Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of ‘‘large accelerated filer,’’ ‘‘accelerated filer,’’ ‘‘smaller reporting company,’’ and ‘‘emerging growth company’’ in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding ordinary shares of the registrant as of ~~August 3, 2022~~July 27, 2023 was ~~86,820,111~~98,983,261.
.

As used in this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise indicates, references to “Wave,” the “Company,” “we,” “our,” “us” or similar terms refer to Wave Life Sciences Ltd. and our wholly-owned subsidiaries.

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that relate to future events or to our future operations or financial performance. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. In some cases, forward-looking statements are identified by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “goals,” “intend,” “likely,” “may,” “might,” “ongoing,” “objective,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “strategy,” “target,” “will” and “would” or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements, other than statements of historical fact, about, among other things: our ability to fund our future operations; our financial position, revenues, costs, expenses, uses of cash and capital requirements; our need for additional financing or the period for which our existing cash resources will be sufficient to meet our operating requirements; the success, progress, number, scope, cost, duration, timing or results of our research and development activities, preclinical studies and clinical trials, including the timing for initiation or completion of or availability of results from any preclinical studies and clinical trials or for submission, review or approval of any regulatory filing; the timing of, and our ability to, obtain and maintain regulatory approvals for any of our product candidates; the potential benefits that may be derived from any of our product candidates; our strategies, prospects, plans, goals, expectations, forecasts or objectives; the success of our collaborations with third parties; any payment that our collaboration partners may make to us; our ability to identify and develop new product candidates; our intellectual property position; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding future expenses and needs for additional financing; our ability to develop sales and marketing capabilities; our ability to identify, recruit and retain key personnel; our financial performance; developments and projections relating to our competitors in the industry; our liquidity and working capital requirements; the expected impact of new accounting standards; and our expectations regarding the impact of ~~COVID-19~~the coronavirus (“COVID-19”) and variants thereof on our business, including on our research and development activities, preclinical studies and clinical trials, supply of drug product, and workforce.

Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on our estimates or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results, level of activity, performance or achievements expressed or implied by any forward-looking statement to differ. These risks, uncertainties and other factors include, among other things, our critical accounting policies; the ability of our preclinical studies to produce data sufficient to support the filing of global clinical trial applications and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results and timing of our programs, which may not support further development of our product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing current and future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to fund our operations and to raise additional capital as needed; competition from others developing therapies for similar uses; ~~the severity and duration of the COVID-19 pandemic;~~ ~~the COVID-19 pandemic, and variants thereof, may negatively impact the conduct of, and the timing of enrollment, completion and reporting with respect to, our clinical trials;~~ any ~~other~~ impacts on our business as a result of or related to the COVID-19 pandemic, the conflict involving Russia and Ukraine, global economic uncertainty, rising inflation, rising interest rates or market disruptions, , as well as other risks and uncertainties under the caption “Risk Factors” contained in this Quarterly Report on Form 10-Q and in other filings we make with the Securities and Exchange ~~Commission.~~Commission (the “SEC”).

Each forward-looking statement contained in this report is based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. As a result of these factors, we cannot assure you that the forward-looking statements in this ~~report~~Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, these statements should not be regarded as representations or warranties by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. We caution you not to place undue reliance on any forward-looking statement.

In addition, any forward-looking statement in this report represents our views only as of the date of this report and should not be relied upon as representing our views as of any subsequent date. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

The Wave Life Sciences Ltd. and Wave Life Sciences Pte. Ltd. names, the Wave Life Sciences mark, PRISM and the other registered and pending trademarks, trade names and service marks of Wave Life Sciences Ltd. appearing in this Quarterly Report on Form 10-Q are the property of Wave Life Sciences Ltd. This Quarterly Report on Form 10-Q also contains additional trade names, trademarks and service marks belonging to Wave Life Sciences Ltd. and to other companies. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q are referred to without the ® and ™ symbols, but such reference should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

The accompanying notes are an integral part of the unaudited consolidated financial statements.

UNAUDITED CONSOLIDATED STATEMENTS OF SERIES A PREFERRED SHARES AND SHAREHOLDERS’ EQUITY (DEFICIT)


	Series A Preferred Shares				Ordinary Shares				Additional Paid-In-		Accumulated Other Comprehensive			Accumulated			Total Shareholders’			Series A Preferred Shares				Ordinary Shares				Additional Paid-In-		Accumulated Other Comprehensive			Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Income (Loss)			Deficit			Equity			Shares		Amount		Shares		Amount		Capital		Income (Loss)			Deficit			Equity (Deficit)
Balance at December 31, 2020		3,901,348	$	7,874		48,778,678	$	694,085	$	71,573	$	389		$	(683,269	)	$	82,778
Balance at December 31, 2021																					3,901,348	$	7,874		59,841,116	$	749,851	$	87,980	$	181		$	(805,514	)	$	32,498
Issuance of ordinary shares pursuant to the at-the-market equity program, net		—		—		844,796		8,028		—		—			—			8,028			—		—		458,092		1,167		—		—			—			1,167
Share-based compensation		—		—		—		—		4,063		—			—			4,063			—		—		—		—		3,971		—			—			3,971
Vesting of RSUs		—		—		155,184		—		—		—			—			—			—		—		468,226		—		—		—			—			—
Option exercises		—		—		31,957		200		—		—			—			200			—		—		15,000		37		—		—			—			37
Issuance of ordinary shares under the ESPP		—		—		44,036		336		—		—			—			336			—		—		77,534		174		—		—			—			174
Other comprehensive loss		—		—		—		—		—		(120	)		—			(120	)		—		—		—		—		—		(86	)		—			(86	)
Net loss		—		—		—		—		—		—			(42,464	)		(42,464	)		—		—		—		—		—		—			(37,814	)		(37,814	)
Balance at March 31, 2021		3,901,348	$	7,874		49,854,651	$	702,649	$	75,636	$	269		$	(725,733	)	$	52,821
Issuance of ordinary shares pursuant to the at-the-market equity program, net		—		—		718,179		5,065		—		—			—			5,065
Balance at March 31, 2022																					3,901,348	$	7,874		60,859,968	$	751,229	$	91,951	$	95		$	(843,328	)	$	(53	)
Issuance of ordinary shares, net of offering costs																					—		—		25,464,483		51,220		—		—			—			51,220
Issuance of pre-funded warrants, net of offering costs																					—		—		—		—		14,268		—			—			14,268
Share-based compensation		—		—		—		—		2,722		—			—			2,722			—		—		—		—		6,950		—			—			6,950
Vesting of RSUs		—		—		3,636		—		—		—			—			—			—		—		400,207		—		—		—			—			—
Other comprehensive loss																					—		—		—		—		—		(142	)		—			(142	)
Net loss		—		—		—		—		—		—			(38,766	)		(38,766	)		—		—		—		—		—		—			(41,296	)		(41,296	)
Balance at June 30, 2021		3,901,348	$	7,874		50,576,466	$	707,714	$	78,358	$	269		$	(764,499	)	$	21,842
Balance at June 30, 2022																					3,901,348	$	7,874		86,724,658	$	802,449	$	113,169	$	(47	)	$	(884,624	)	$	30,947

The accompanying notes are an integral part of the unaudited consolidated financial statements.

UNAUDITED CONSOLIDATED STATEMENTS OF SERIES A PREFERRED SHARES AND SHAREHOLDERS’ EQUITY (DEFICIT) CONTINUED


	Series A Preferred Shares				Ordinary Shares				Additional Paid-In-		Accumulated Other Comprehensive			Accumulated			Total Shareholders’			Series A Preferred Shares				Ordinary Shares				Additional Paid-In-		Accumulated Other Comprehensive			Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Income (Loss)			Deficit			Equity (Deficit)			Shares		Amount		Shares		Amount		Capital		Income (Loss)			Deficit			Equity (Deficit)
Balance at December 31, 2021		3,901,348	$	7,874		59,841,116	$	749,851	$	87,980	$	181		$	(805,514	)	$	32,498
Issuance of ordinary shares pursuant to the at-the-market equity program, net		—		—		458,092		1,167		—		—			—			1,167
Balance at December 31, 2022																					3,901,348	$	7,874		86,924,643	$	802,833	$	119,442	$	(29	)	$	(967,337	)	$	(45,091	)
Issuance of ordinary shares																					—		—		10,683,761		34,623		—		—			—			34,623
Share-based compensation		—		—		—		—		3,971		—			—			3,971			—		—		—		—		2,750		—			—			2,750
Vesting of RSUs		—		—		468,226		—		—		—			—			—			—		—		363,161		—		—		—			—			—
Option exercises		—		—		15,000		37		—		—			—			37			—		—		181		1		—		—			—			1
Issuance of ordinary shares under the ESPP		—		—		77,534		174		—		—			—			174			—		—		133,098		429		—		—			—			429
Other comprehensive loss		—		—		—		—		—		(86	)		—			(86	)		—		—		—		—		—		(21	)		—			(21	)
Net loss		—		—		—		—		—		—			(37,814	)		(37,814	)		—		—		—		—		—		—			(27,405	)		(27,405	)
Balance at March 31, 2022		3,901,348	$	7,874		60,859,968	$	751,229	$	91,951	$	95		$	(843,328	)	$	(53	)
Issuance of ordinary shares, net of offering costs		—		—		25,464,483		51,220		—		—			—			51,220
Issuance of pre-funded warrants, net of offering costs		—		—		—		—		14,268		—			—			14,268
Balance at March 31, 2023																					3,901,348	$	7,874		98,104,844	$	837,886	$	122,192	$	(50	)	$	(994,742	)	$	(34,714	)
Issuance of ordinary shares pursuant to the at-the-market equity program, net																					—		—		429,051		1,704		—		—			—			1,704
Share-based compensation		—		—		—		—		6,950		—			—			6,950			—		—		—		—		2,409		—			—			2,409
Vesting of RSUs		—		—		400,207		—		—		—			—			—			—		—		9,234		—		—		—			—			—
Option exercises																									23,687		85										85
Other comprehensive loss		—		—		—		—		—		(142	)		—			(142	)		—		—						—		(100	)		—			(100	)
Net loss		—		—		—		—		—		—			(41,296	)		(41,296	)		—		—		—		—		—		—			(21,104	)		(21,104	)
Balance at June 30, 2022		3,901,348	$	7,874		86,724,658	$	802,449	$	113,169	$	(47	)	$	(884,624	)	$	30,947
Balance at June 30, 2023																					3,901,348	$	7,874		98,566,816	$	839,675	$	124,601	$	(150	)	$	(1,015,846	)	$	(51,720	)

The accompanying notes are an integral part of the unaudited consolidated financial statements.

1. THE COMPANY

Organization

Wave Life Sciences Ltd. (together with its subsidiaries, “Wave” or the “Company”) is a clinical-stage ~~genetic~~RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Using PRISM, Wave’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of novel stereopure ~~oligonucleotides.~~oligonucleotides, Wave ~~has built a genetic toolkit comprised~~is working to develop best- or first-in-class medicines that target the transcriptome (the full set of ~~multiple therapeutic modalities, including RNase-H mediated silencing, RNAi, splicing, and RNA base editing, all of which leverage learnings and optimizations~~ribonucleic acid (“RNA”) molecules produced from the ~~PRISM platform and allow Wave~~human genome) to ~~design built-for-purpose molecules to optimally address disease biology.~~treat genetically defined diseases with a high degree of unmet need.

The Company was incorporated in Singapore on July 23, 2012 and has its principal U.S. office in Cambridge, Massachusetts. The Company was incorporated with the purpose of combining two commonly held companies, Wave Life Sciences USA, Inc. (“Wave USA”), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (“Wave Japan”), a company organized under the laws of Japan (formerly Chiralgen., Ltd.), which occurred on September 13, 2012. On May 31, 2016, Wave Life Sciences Ireland Limited (“Wave Ireland”) was formed as a wholly-owned subsidiary of Wave Life Sciences Ltd. On April 3, 2017, Wave Life Sciences UK Limited (“Wave UK”) was formed as a wholly-owned subsidiary of Wave Life Sciences Ltd.

The Company’s primary activities since inception have been developing and evolving PRISM to design, develop and commercialize oligonucleotide therapeutics, advancing the Company’s differentiated ~~neurology~~ portfolio, ~~as well as exploring other therapeutic areas of interest,~~ building the Company’s research, development and manufacturing capabilities, advancing programs into the clinic, furthering clinical development of such clinical-stage programs, building the Company’s intellectual property, and assuring adequate capital to support these activities.

Liquidity

Since its inception, the Company has not generated any product revenue and has incurred recurring net losses. To date, the Company has primarily funded its operations through private placements of debt and equity securities, public and other registered offerings of its equity securities and collaborations with third parties. Until the Company can generate significant revenue from product sales, if ever, the Company expects to continue to finance operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The inability to raise capital as and when needed would have a negative impact on the Company’s financial condition and ability to pursue its business strategy.

As of June 30, ~~2022,~~2023, the Company had cash and cash equivalents ~~and short-term investments~~ of $~~148.2~~173.0 million. The Company expects that its existing cash and cash equivalents ~~and short-term investments~~ will be sufficient to fund its operations for at least the next twelve months. The Company has based this expectation on assumptions that may prove to be incorrect, and the Company may use its available capital resources sooner than it currently expects. If the Company’s anticipated operating results are not achieved in future periods, planned expenditures may need to be further reduced in order to extend the time period over which the then-available resources would be able to fund the Company’s operations. In addition, the Company may elect to raise additional funds before it needs them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if the Company expects it has sufficient funds for its current or future operating plans.

Risks and Uncertainties

The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, maintaining internal manufacturing capabilities, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. The Company’s therapeutic programs will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company’s research and development efforts will be successful, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.

Basis of Presentation

The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) and in U.S. dollars.

2. SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies described in the Company’s audited financial statements as of and for the year ended December 31, ~~2021,~~2022, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, filed with the Securities and Exchange Commission (“SEC”) on March ~~3, 2022,~~23, 2023, as amended (the ~~“2021~~“2022 Annual Report on Form 10-K”), have had no material changes during the six months ended June 30, ~~2022,~~2023, except as described below.

~~Fair Value~~Use of ~~Financial Instruments~~

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:

~~Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets.~~

Level 2—Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security.

Level 3—Pricing inputs are unobservable for the asset, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset. Level 3 includes private investments that are supported by little or no market activity.

~~Cash and Cash Equivalents~~

The Company considers all highly liquid securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents are comprised of funds in cash and money market accounts.

~~Short-Term Investments~~Estimates

The ~~Company considers all time deposits~~Company’s consolidated financial statements are prepared in accordance with ~~original maturities~~U.S. GAAP. The preparation of ~~more than three months from~~ the ~~date of purchase to be short-term investments.~~

~~Concentration of Credit Risk~~

~~Cash, cash equivalents, restricted cash~~Company’s financial statements and ~~short-term investments are financial instruments that potentially subject~~related disclosures requires the Company to ~~concentration~~make estimates and assumptions that affect the reported amount of ~~credit risk.~~assets, liabilities, revenue, costs and expenses and related disclosures. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The Company ~~uses several financial institutions~~believes that its revenue recognition policy, particularly (a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to ~~maintain~~the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in the Company’s analysis of contracts with contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”) to estimate the contract expense, involve a greater degree of judgment, and therefore the Company considers them to be its ~~cash, cash equivalents, restricted cash and short-term investments, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk.~~critical accounting policies. The Company ~~has not experienced any losses in such accounts~~evaluates its estimates and ~~management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.~~assumptions on an ongoing basis. The ~~Company has no financial instruments with off-balance sheet risk of loss.~~Company’s actual results may differ from these estimates under different assumptions and conditions.

Unaudited Interim Financial Data

The accompanying interim consolidated balance sheet as of June 30, ~~2022,~~2023, the related interim consolidated statements of operations and comprehensive loss for the three and six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, the consolidated statements of Series A preferred shares and shareholders’ equity (deficit) for the three months ended March 31, ~~and~~ June 30, ~~2022~~2023 and ~~2021,~~2022, the consolidated statements of cash flows for the six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, and the related interim information contained within the notes to the unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. The financial data and other information disclosed in these notes related to the three and six months ended June 30, ~~2022~~2023 and ~~2021~~2022 are unaudited. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three and six months ended June 30, ~~2022~~2023 and ~~2021.~~2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, ~~2022~~2023 or any other interim period or future year or period.

3. ~~FAIR VALUE MEASUREMENTS~~ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

~~The following table sets forth~~Accrued expenses and other current liabilities consist of the ~~Company’s financial assets that are measured at fair value on a recurring basis:~~following:

Total

Level 1

Level 2

Level 3

(in thousands)

June 30, 2022

Cash and cash equivalents

$
123,163

$
123,163

$
—

$
—

Short-term investments

25,000

—

25,000

—

Restricted cash

3,651

3,651

—

—

Total

$
151,814

$
126,814

$
25,000

$
—

December 31, 2021

Cash and cash equivalents

$
150,564

$
150,564

$
—

$
—

Short-term investments

—

—

—

—

Restricted cash

3,651

3,651

—

—

Total

$
154,215

$
154,215

$
—

$
—


	June 30, 2023		December 31, 2022
	(in thousands)
Accrued compensation	$	6,898	$	12,287
Accrued expenses related to CROs and CMOs		2,662		3,516
Accrued expenses and other current liabilities		869		1,749
Total accrued expenses and other current liabilities	$	10,429	$	17,552

~~There have been~~ 0 ~~transfers between fair value levels during the three months ended June 30, 2022.~~

Cash, cash equivalents and restricted cash are Level 1 assets which are comprised of funds held in checking and money market accounts. Short-term investments are Level 2 assets which are comprised of time deposits with original maturities of more than three months. The Company determined that the fair value of its short-term investments is $~~25.0~~ ~~million as of June 30, 2022, which approximates the carrying value of the term deposits. There were~~ 0 short-term investments as of December 31, 2021, as the term deposits that constitute the Company’s short-term investments were purchased during the six months ended June 30, 2022. The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities.

4. SHARE-BASED COMPENSATION

The Wave Life Sciences Ltd. 2021 Equity Incentive Plan ~~(the “2021 Plan”)~~ was approved by the Company’s shareholders and went into effect on August 10, ~~2021.~~2021 and was amended effective as of August 9, 2022 (as amended, the “2021 Plan”). The 2021 Plan serves as the successor to the Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended (the “2014 Plan”), such that outstanding awards granted under the 2014 Plan continue to be governed by the terms of the 2014 Plan, but no awards may be made under the 2014 Plan after August 10, 2021. The aggregate number of ordinary shares authorized for issuance of awards under the 2021 Plan iswas originally 5,450,000 ordinary shares, and was subsequently increased to 11,450,000 in August 2022, plus the number of ordinary shares underlying any awards under the 2014 Plan that are forfeited, cancelled or otherwise terminated (other than by exercise or withheld by the Company to satisfy any tax withholding obligation) on or after August 10, 2021.

The 2021 Plan authorizes (and the 2014 Plan previously authorized) the ~~Company’s~~ board of directors or a committee of the board of directors to, among other things, grant non-qualified share options, restricted awards, which include restricted shares and restricted share units (“RSUs”), and performance awards to eligible employees and directors of the Company. The Company accounts for grants to its non-employee directors as grants to employees.

Options generally vest over periods of one to four years, and ~~any~~ options that are forfeited or cancelled are available to be granted again. The contractual life of options is generally five or ten years from the grant date. RSUs can be time-based or performance-based. Time-based RSUs generally vest over a period of one to four years. The vesting of performance-based RSUs is contingent on the achievement of certain performance milestones. Any RSUs that are forfeited are available to be granted again.

In March 2021, the compensation committee of the Company’s board of directors approved an amendment and restatement of the Company’s outstanding 2019 performance-based RSUs to add an additional milestone to the existing milestones. In 2021, the Company also granted performance-based RSUs with the same terms to certain employees who did not receive the 2019 performance-based RSUs. This modification did not result in any incremental expense.

~~In April 2022, the Company determined that a performance-based RSU milestone was achieved and consequently~~ 50~~% of the outstanding performance-based RSUs vested, which resulted in the issuance of~~ ~~384,646~~ ~~ordinary shares. During the three months ended June 30, 2022, the Company recorded share-based compensation expense of approximately $3.8~~ million, which represents all of the expense related to the achievement of this performance-based RSU milestone. The Company did not recognize any expense related to the other performance-based RSU milestones, as the remaining milestones were not considered probable of achievement as of June 30, 2022.

During the six months ended June 30, ~~2022,~~2023, the Company granted an aggregate of ~~2,037,175~~4,984,750 options and ~~55,075~~101,700 time-based RSUs to employees.

As of June 30, ~~2022,~~2023, ~~1,561,172~~1,756,326 ordinary shares remained available for future grant under the 2021 Plan.

The Wave Life Sciences Ltd. 2019 Employee Share Purchase Plan (“ESPP”) allows ~~all~~ full-time and certain part-time employees to purchase the Company’s ordinary shares at a discount to fair market value. Eligible employees may enroll in a six-month offering period beginning ~~on or about~~every January 15th15th and July 15th ~~every year. Shares~~15th. Ordinary shares are purchased at a price equal to 85% of the lower of the fair market value of the Company’s ordinary shares on the first business day or the last business day of an offering period. During the six months ended June 30, ~~2022,~~2023, ~~77,534~~133,098 ordinary shares were issued under the ESPP. As of June 30, ~~2022,~~2023, there were ~~804,940~~583,315 ordinary shares available for issuance under the ESPP.

5. COLLABORATION AGREEMENTS

GSK Collaboration and Equity Agreements

On December 13, 2022, Wave USA and Wave UK entered into a Collaboration and License Agreement (the “GSK Collaboration Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) (“GSK”). Pursuant to the GSK Collaboration Agreement, Wave and GSK have agreed to collaborate on the research, development, and commercialization of oligonucleotide therapeutics, including an exclusive global license to WVE-006. The discovery collaboration component has an initial four-year research term and combines Wave’s proprietary discovery and drug development platform, PRISM, with GSK’s unique insights from human genetics and its global development and commercial capabilities. On January 27, 2023, the GSK Collaboration Agreement became effective, and GSK paid Wave an upfront payment of $120.0 million.

Simultaneously with the execution of the GSK Collaboration Agreement, Wave entered into a Share Purchase Agreement (the “SPA”) on December 13, 2022, with Glaxo Group Limited (“GGL”), an affiliate of GSK, pursuant to which Wave agreed to sell 10,683,761 of its ordinary shares to GGL at a purchase price of $4.68 per share (the “GSK Equity Investment”). The GSK Equity Investment closed on January 26, 2023, following the completion of customary closing conditions. The ordinary shares purchased by GGL are subject to lock-up and standstill restrictions and carry certain registration rights, customary for transactions of this kind. The Company did not incur any material costs in connection with the issuance of the ordinary shares under the SPA.

The GSK Collaboration Agreement has three components:

An exclusive global license for GSK to WVE-006, the Company’s preclinical, first-in-class A-to-I(G) RNA editing candidate for alpha-1 antitrypsin deficiency, with development and commercialization responsibilities transferring to GSK after the Company completes the first-in-patient study (the “AATD Collaboration”). The Company will be responsible for preclinical, regulatory, manufacturing, and clinical activities for WVE-006 through the initial Phase 1/2 study, at the Company’s sole cost. Thereafter, GSK will be responsible for advancing WVE-006 through pivotal studies, registration, and global commercialization at GSK’s sole cost;

A discovery research collaboration which enables GSK to advance up to eight programs leveraging PRISM and the Company’s oligonucleotide expertise and discovery capabilities (the “Discovery Research Collaboration”); and

A discovery collaboration which enables the Company to advance up to three programs leveraging targets informed by GSK’s novel insights (“Wave’s Collaboration Programs”).

Under the GSK Collaboration Agreement, each party grants to the other party certain licenses to the collaboration products to enable the other party to perform its obligations and exercise its rights under the GSK Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the GSK Collaboration Agreement. The parties’ exclusivity obligations to each other are limited on a target-by-target basis with regard to targets in the collaboration. GSK may terminate the GSK Collaboration Agreement for convenience, in its entirety or on a target-by-target basis. Subject to certain exceptions, each party has the right to terminate the GSK Collaboration Agreement on a target-by-target basis if the other party, or a related party, challenges the patentability, enforceability or validity of any patents within the licensed technology that cover any product that is subject to the GSK Collaboration Agreement. In the event of any material breach of the GSK Collaboration Agreement by a party, subject to cure rights, the other party may terminate the GSK Collaboration Agreement in its entirety if the breach relates to all targets or on a target-by-target basis if the breach relates to a specific target. In the event that GSK and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the GSK Collaboration Agreement and directed to a particular target, the Company may terminate the GSK Collaboration Agreement with respect to such target. Either party may terminate the GSK Collaboration Agreement for the other party’s insolvency. In certain termination circumstances, the Company would receive a license from GSK to continue researching, developing and manufacturing certain products.

The GSK Collaboration Agreement, unless terminated earlier, will continue until the date on which: (i) with respect to a validation target, the date on which such validation target is not advanced into a collaboration program; or (ii) with respect to a collaboration target, the royalty term has expired for all collaboration products directed to the applicable collaboration target. The GSK Collaboration Agreement includes options to extend the research term for up to three additional years, which would increase the number of programs available to both parties. The Company will lead all preclinical research for GSK and the Company’s collaboration programs up to investigational new drug (“IND”)-enabling studies. The Company will lead IND-enabling studies, clinical development and commercialization for the Company’s collaboration programs. GSK collaboration programs will transfer to GSK for IND-enabling studies, clinical development and commercialization.

The GSK Collaboration Agreement is managed by a joint steering committee in which both parties are represented equally. In addition, the AATD Collaboration is overseen by a joint development committee, a joint patent committee advises on intellectual property activities, and the Discovery Research Collaboration is overseen by a joint research committee. Both parties are represented equally for these committees and report to the joint steering committee.

The Company assessed this arrangement in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) and concluded that the contract counterparty, GSK, is a customer for the AATD Collaboration prior to GSK exercising its option and, for the Discovery Research Collaboration programs during the target validation research term. The Company identified the following material promises under the arrangement: (1) the exclusive global license for WVE-006; (2) the research and development services for WVE-006 through the Phase 1/2 study; (3) the discovery research services under the Discovery Research Collaboration to perform target validation programs; (4) research and development license for the Discovery Research Collaboration; and (5) the research and development services for the GSK collaboration programs through completion of a candidate selection. The research and development services for WVE-006 were determined to not be distinct from the exclusive global license and should therefore be combined into a single performance obligation for the AATD Collaboration. The research and development services for the Discovery Research Collaboration were determined to not be distinct from the research and development license for the Discovery Research Collaboration and should therefore be combined into a single performance obligation. In addition, the Company determined that the option to advance up to eight programs from the Discovery Research Collaboration was priced at fair value and did not provide a material right to GSK.

Based on these assessments, the Company identified two performance obligations in the GSK Collaboration Agreement: (1) AATD Collaboration consisting of the research and development services through completion of the Phase 1/2 study and research and development license for WVE-006 and (2) Discovery Research Collaboration which consists of research and development services for validating the targets and license for research and development license for targets.

At the outset of the arrangement, the transaction price included fixed consideration of the $120.0 million upfront, the $15.4 million in premium related to the GSK Equity Investment and the estimated variable consideration related to the additional target validation research funding. The Company allocated the estimated variable consideration to the Discovery Research Collaboration programs and then allocated the fixed consideration to the performance obligations on a relative standalone selling price basis. The Company determined that the GSK Collaboration Agreement did not contain a significant financing component. The program initiation fees to research and preclinically develop the GSK collaboration programs and the additional potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the GSK Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period, and as uncertain events are resolved or other changes in circumstances occur, the Company will adjust its estimate of the transaction price.

~~5. COLLABORATION AGREEMENTS~~The Company developed the estimated standalone selling price for the global license for WVE-006, under the AATD Collaboration, using a discounted cash flow model. For the performance obligation associated with the research and development services under the Discovery Research Collaboration and the research and development services for WVE-006 under the AATD Collaboration, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company’s best estimate of the length of time required to perform the services.

Revenue associated with the AATD Collaboration performance obligation is being recognized as the research and development services are provided using an input measure, according to the costs incurred and the total costs expected to be incurred to satisfy the performance obligation. The revenue associated with the Discovery Research Collaboration performance obligation is being recognized as the research and development services are provided using an input measure, according to the costs incurred and the total costs expected to be incurred to satisfy the performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company’s consolidated balance sheet. Additional funding related to the Company’s research activities related to Discovery Research Collaboration will be recorded as accounts receivable when contractually enforceable and recorded as deferred revenue, or as revenue as the services are provided.

During the three and six months ended June 30, 2023, the Company recognized revenue of approximately $20.8 million and $33.1 million, respectively, under the GSK Collaboration Agreement using the input method described above.

The aggregate amount of the transaction price allocated to the Company’s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue on June 30, 2023 is approximately $106.3 million, of which $81.2 million is included in current liabilities and $25.1 million is included in long-term liabilities.

Takeda Collaboration and Equity Agreements

In February 2018, Wave USA and Wave UK entered into a global strategic collaboration (the “Takeda Collaboration”) with Takeda Pharmaceutical Company Limited (“Takeda”), pursuant to which Wave USA, Wave UK and Takeda agreed to collaborate on the research, development and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System (“CNS”). The Takeda Collaboration provides the Company with at least $230.0 million in committed cash and Takeda with the option to co-develop and co-commercialize the Company’s CNS development programs in (1) Huntington’s disease (“HD”); (2) amyotrophic lateral sclerosis (“ALS”) and frontotemporal dementia (“FTD”); and (3) the Company’s discovery-stage program targeting ATXN3 for the treatment of spinocerebellar ataxia 3 (“SCA3”) (collectively, “Category 1 Programs”). In addition, the Takeda Collaboration provided Takeda the right to exclusively license multiple preclinical programs for CNS disorders, including Alzheimer’s disease and Parkinson’s disease (collectively, “Category 2 Programs”). In April 2018, the Takeda Collaboration became effective and Takeda paid the Company $110.0 million as an upfront payment. Takeda also agreed to fund the Company’s research and preclinical activities in the amount of $60.0 million during the four-year research term and to reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by ~~the Company~~Wave that exceed that amount.

Simultaneously with Wave USA and Wave UK’s entry into the collaboration and license agreement with Takeda (the “Takeda Collaboration Agreement”), the Company entered into a share purchase agreement with Takeda (the “Takeda Equity Agreement,” and together with the Takeda Collaboration Agreement, the “Takeda Agreements”) pursuant to which it agreed to sell to Takeda 1,096,892 of its ordinary shares at a purchase price of $54.70 per share. In April 2018, the Company closed the Takeda Equity Agreement and received aggregate cash proceeds of $60.0 million. The Company did not incur any material costs in connection with the issuance of the shares.

With respect to Category 1 Programs, the Company will be responsible for researching and developing products and companion diagnostics for Category 1 Programs through completion of the first proof of mechanism study for such products. Takeda will have an exclusive option for each target and all associated products and companion diagnostics for such target, which it may exercise at any time through completion of the proof of mechanism study. If Takeda exercises this option, the Company will receive an opt-in payment and will lead manufacturing and joint clinical co-development activities and Takeda will lead joint co-commercial activities in the United States and all commercial activities outside of the United States. Global costs and potential profits will be shared 50:50 and the Company will be eligible to receive development and commercial milestone payments. In addition to its 50% profit share, the Company is eligible to receive option exercise fees and development and commercial milestone payments for each of the Category 1 Programs.

With respect to Category 2 Programs, the Company granted Takeda the right to exclusively license multiple preclinical programs during a four-year research term (subject to limited extension for programs that were initiated prior to the expiration of the research term, in accordance with the Takeda Collaboration Agreement) (“Category 2 Research Term”). During that term, the Takeda Collaboration provided that the parties may collaborate on preclinical programs for up to 6six targets at any one time. The Company was responsible for researching and preclinically developing products and companion diagnostics directed to the agreed upon targets through completion of Investigational New Drug application (“IND”)-enabling studies in the first major market country. Thereafter, Takeda would have an exclusive worldwide license to develop and commercialize products and companion diagnostics directed to such targets, subject to the Company’s retained rights to lead manufacturing activities for products directed to such targets. Takeda agreed to fund the Company’s research and preclinical activities in the amount of $60.0 million during the research term and reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by the Company that exceeded that amount. The Company was also eligible to receive tiered high single-digit to mid-teen royalties on Takeda’s global commercial sales of products from each Category 2 Program.

Under the Takeda Collaboration Agreement, each party granted to the other party specific intellectual property licenses to enable the other party to perform its obligations and exercise its rights under the Takeda Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the Takeda Collaboration Agreement.

The term of the Takeda Collaboration Agreement commenced on April 2, 2018 and, unless terminated earlier, will continue until the date on which: (i) with respect to each Category 1 Program target for which Takeda does not exercise its option, the expiration or termination of the development program with respect to such target; (ii) with respect to each Category 1 Program target for which Takeda exercises its option, the date on which neither party is researching, developing or manufacturing any products or companion diagnostics directed to such target; or (iii) with respect to each Category 2 Program target, the date on which royalties are no longer payable with respect to products directed to such target.

Takeda may terminate the Takeda Collaboration Agreement for convenience on 180 days’ notice, in its entirety or on a target-by-target basis. Subject to certain exceptions, each party has the right to terminate the Takeda Collaboration Agreement on a target-by-target basis if the other party, or a third party related to such party, challenges the patentability, enforceability or validity of any patents within the licensed technology that cover any product or companion diagnostic that is subject to the Takeda Collaboration Agreement. In the event of any material breach of the Takeda Collaboration Agreement by a party, subject to cure rights, the other party may terminate the Takeda Collaboration Agreement in its entirety if the breach relates to all targets or on a target-by-target basis if the breach relates to a specific target. In the event that Takeda and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the Takeda Collaboration Agreement and directed to a particular target, the Company may terminate the Takeda Collaboration Agreement with respect to such target. Either party may terminate the Takeda Collaboration Agreement for the other party’s insolvency. In certain termination circumstances, the Company would receive a license from Takeda to continue researching, developing and manufacturing certain products, and companion diagnostics.

The Takeda Collaboration is managed by a joint steering committee ~~(“JSC”)~~ in which both parties are represented equally. The ~~JSC~~joint steering committee is tasked with overseeing the scientific progression of each Category 1 Program and, prior to the Amendment (discussed below), the Category 2 Programs.

The Company assessed this arrangement in accordance with ASC ~~Topic~~ 606 ~~Revenue from Contracts with Customers (“ASC 606”)~~ and concluded that the contract counterparty, Takeda, is a customer for Category 1 Programs prior to Takeda exercising its option, and for Category 2 Programs during the Category 2 Research Term. The Company identified the following material promises under the arrangement: (1) the non-exclusive, royalty-free research and development license for each Category 1 Program; (2) the research and development services for each Category 1 Program through completion of the first proof of mechanism study; (3) the exclusive option to license, co-develop and co-commercialize each Category 1 Program; (4) the right to exclusively license the Category 2 Programs; and (5) the research and preclinical development services of the Category 2 Programs through completion of IND-enabling studies. The research and development services for each Category 1 Program were determined to not be distinct from the research and development license and should therefore be combined into a single performance obligation for each Category 1 Program. The research and preclinical development services for the Category 2 Programs were determined to not be distinct from the exclusive licenses for the Category 2 Programs and ~~should~~ therefore bewere combined into a single performance obligation.

Additionally, the Company determined that the exclusive option for each Category 1 Program was priced at a discount, and, as such, provide material rights to Takeda, representing three separate performance obligations. Based on these assessments, the Company identified seven performance obligations in the Takeda Collaboration Agreement: (1) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; (2) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; (3) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; (4) the material right provided for the exclusive option to license, co-develop and co-commercialize HD; (5) the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; (6) the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3; and (7) the research and preclinical development services and right to exclusively license the Category 2 Programs.

At the outset of the arrangement, the transaction price included the $110.0 million upfront consideration received and the $60.0 million of committed research and preclinical funding for the Category 2 Programs. The Company determined that the Takeda Collaboration Agreement did not contain a significant financing component. The option exercise fees to license, co-develop and co-commercialize each Category 1 Program that may be received are excluded from the transaction price until each customer option is exercised. The potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the Takeda Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, if necessary, will adjust its estimate of the transaction price.

The Company allocated the transaction price to the performance obligations on a relative standalone selling price basis. For the performance obligations associated with the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; and the research and preclinical development services and right to exclusively license the Category 2 Programs, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company’s best estimate of the length of time required to perform the services. For the performance obligations associated with the material right provided for the exclusive option to license, co-develop and co-commercialize HD; the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; and the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3, the Company estimated the standalone fair value of the option to license each Category 1 Program utilizing an adjusted market assessment approach, and determined that any standalone fair value in excess of the amounts to be paid by Takeda associated with each option represented a material right.

Revenue associated with the research and development services for each Category 1 Program performance obligation is being recognized as the research and development services are provided using an input method, according to the costs incurred on each Category 1 Program and the total costs expected to be incurred to satisfy each Category 1 Program performance obligation. ~~Revenue~~Prior to the Amendment (as defined below), revenue associated with the research and preclinical development services for the Category 2 Programs performance obligation ~~is being~~was recognized as the research and preclinical development services are provided using an input method, according to the costs incurred on Category 2 Programs and the total costs expected to be incurred to satisfy the performance obligation. The transfer of control for these performance obligations occurs over time and, in management’s judgment, this input method is the best measure of progress towards satisfying the performance obligations. The amount allocated to the material right for each Category 1 Program option will be recognized on the date that Takeda exercises each respective option, or immediately as each option expires unexercised. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company’s consolidated balance sheet.

On October 15, 2021, Wave USA, Wave UK and Takeda entered into the Second Amendment to the Takeda Collaboration Agreement (the “Amendment”), which discontinued the Category 2 component of the Takeda Collaboration. The Category 1 Programs under the Collaboration Agreement remain in effect and are unchanged by the Amendment. Pursuant to the Amendment, Takeda agreed to pay the Company an additional $22.5 million as full payment for reimbursable Category 2 ~~Program~~Programs collaboration-budgeted research and preclinical expenses. The Company received this payment from Takeda related to the Category ~~1 Programs under~~2 component and recognized the ~~Takeda Collaboration Agreement remain~~full amount as collaboration revenue in ~~effect and are unchanged by~~ the ~~Amendment.~~year ended December 31, 2021.

Through June 30, ~~2022,~~2023, the Company had recognized revenue of ~~approximately~~ $~~79.8~~83.2 million as collaboration revenue under the Takeda Collaboration ~~Agreement.~~Agreement in the Company’s consolidated statements of operations and comprehensive loss. During the three and six months ended June 30, ~~2022,~~2023, the Company recognized revenue of $~~0.3~~1.3 million and $~~1.9~~2.0 million under the Takeda Collaboration Agreement, respectively. During the three and six months ended June 30, ~~2021,~~2022, the Company recognized revenue of approximately $~~2.8~~0.3 million and $1.9 million under the Takeda Collaboration ~~Agreement.~~Agreement, respectively.

The aggregate amount of the transaction price allocated to the Company’s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue as of December 31, ~~2021~~2022 was $~~114.2~~111.3 million, of which approximately $~~37.1~~31.6 million was included in current liabilities and $79.8 million was included in long-term liabilities. The aggregate amount of the transaction price allocated to the Company’s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue at June 30, ~~2022~~2023 is $~~112.7~~109.3 million, of which $~~37.5~~29.9 million is included in current liabilities and $79.4 million is included in long-term liabilities. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the research and development services for each Category 1 Program as costs are incurred, over the remaining research term. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the material right for each Category 1 Program option upon Takeda’s exercise or termination of such option, or immediately as each option expires unexercised.

6. ~~SHAREHOLDERS’ EQUITY~~

~~June 2022 Offering~~

~~On June 16, 2022, the Company closed an underwritten offering (the “June 2022 Offering”) in which the Company issued and sold~~ ~~25,464,483~~ ~~of the Company’s ordinary shares at a price of $2.15~~ ~~per share and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to~~ ~~7,093,656~~ ~~of the Company’s ordinary shares at an offering price of $2.1499~~ ~~per Pre-Funded Warrant, which represents the per share offering price for the ordinary shares less the $0.0001~~ per share exercise price for each Pre-Funded Warrant. These Pre-Funded Warrants were recorded as a component of shareholders’ equity within additional paid-in capital. The gross proceeds to the Company were $~~70.0~~ ~~million before deducting underwriting discounts and commissions and other offering expenses. The net proceeds of the June 2022 Offering were approximately $65.5~~ ~~million.~~

The Pre-Funded Warrants are exercisable at any time after their original issuance and on or prior to the five-year anniversary of the original issuance date. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than ~~19.99% of the number of ordinary shares outstanding or more than~~ ~~19.99% of the combined voting power of the Company’s securities outstanding immediately after giving effect to such exercise, unless and until shareholder approval is obtained.~~

7. NET LOSS PER ORDINARY SHARE

The Company applies the two-class method to calculate its basic and diluted net loss per share attributable to ordinary shareholders, as its Series A preferred shares are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to ordinary shareholders.

As of June 30, ~~2022,~~2023, there are 7,093,656 vested and exercisable pre-funded warrants (“Pre-Funded ~~Warrants~~Warrants”) outstanding to purchase ordinary shares for the exercise price of $0.0001 per ~~share.~~share, provided that, unless and until the Company obtains shareholder approval for the issuance of the shares underlying the Pre-Funded Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i) the aggregate number of our ordinary shares beneficially owned by the holder (together with its affiliates) to exceed 19.99% of the number of our ordinary shares outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 19.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. The Pre-Funded Warrants are included in the weighted-average shares outstanding used in the calculation of basic net loss per share as the exercise price is negligible and the warrants are fully vested and exercisable.

Basic loss per share is computed by dividing net loss attributable to ordinary shareholders and Pre-Funded Warrant holders by the weighted-average number of ordinary shares and Pre-Funded Warrants outstanding.

The Company’s potentially dilutive shares, which include outstanding share options to purchase ordinary shares, RSUs, and Series A preferred shares, are considered to be ordinary share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following potential ordinary ~~share equivalents,~~shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to ordinary shareholders for the periods indicated because including them would have had an anti-dilutive effect:


	As of June 30,				As of June 30,
	2022		2021		2023		2022
Options to purchase ordinary shares		8,526,312		4,584,490		14,176,822		8,526,312
RSUs		979,850		2,027,019		626,465		979,850
Series A preferred shares		3,901,348		3,901,348		3,901,348		3,901,348

Additionally, for the periods presented, the two-class method does not impact the net loss per ordinary share as the Company was in a net loss position for each of the periods presented and holders of Series A preferred shares do not participate in losses.

8.7. INCOME TAXES

During the three and six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, the Company recorded 0no income tax provision. The Company maintained a full valuation allowance for the three and six months ended June 30, ~~2022~~2023 and ~~2021~~2022 in all jurisdictions due to uncertainty regarding future taxable income.

The Company’s utilization of its net operating loss carryforwards and general business credit carryforwards in the United States may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. As of June 30, 2022, the Company is evaluating whether an ownership change occurred during 2022. Should an ownership change have occurred or occur in the future, the Company’s ability to utilize its net operating losses and general business credit carryforwards may be limited.

9.8. GEOGRAPHIC DATA

Substantially all of the Company’s long-lived assets were located in the United States as of June 30, ~~2022~~2023 and December 31, ~~2021.~~2022.

~~10.~~9. RELATED ~~PARTIES~~PARTY TRANSACTIONS

The Company had the following related party ~~transaction for the periods presented in the accompanying consolidated financial statements:~~transactions:

•

In 2012, the Company entered into a consulting agreement for scientific advisory services with Dr. Gregory L. Verdine, one of the Company’s founders and a member of the Company’s board of directors. The consulting agreement does not have a specific term and may be terminated by either party upon 14 days’ prior written notice. Pursuant to the consulting agreement, the Company pays Dr. Verdine approximately $13 thousand per month, plus reimbursement for certain expenses. In October 2022, the compensation committee of the Company’s board of directors granted Dr. Verdine a non-qualified share option for 163,467 ordinary shares in lieu of cash as payment under this consulting agreement for the service period of October 1, 2022 through December 31, 2024, the monthly vesting of which is subject to Dr. Verdine’s continued service under the consulting agreement.

•

In April 2023, the Company engaged Shin Nippon Biomedical Laboratories Ltd. (“SNBL”), one of the Company’s shareholders, to provide approximately $2.8 million in certain non-human primate contract research services to the Company and during the three months ended June 30, 2023, the Company paid SNBL $1.4 million for the aforementioned contract research services.

~~11. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES~~10. SUBSEQUENT EVENT

~~Accrued expenses~~In May 2023, the Company announced its decision to discontinue clinical development of WVE-004 for C9orf72-associated ALS and ~~other current liabilities consist~~FTD (“C9-ALS/FTD”). In July 2023, the joint steering committee that manages the Takeda Collaboration terminated C9-ALS/FTD as a target under the collaboration (the “C9 Target”) and consequently Takeda and the Company’s rights and obligations under the Takeda Collaboration were terminated with respect to the C9 Target.

As a result of the ~~following:~~

June 30, 2022

December 31, 2021

(in thousands)

Accrued compensation

$
6,574

$
10,181

Accrued expenses related to CROs and CMOs

3,473

3,571

Accrued expenses and other current liabilities

1,038

1,109

Total accrued expenses and other current liabilities

$
11,085

$
14,861

~~12. LEASES~~

~~Lease Arrangements~~

~~The Company enters into lease arrangements for its facilities. A summary of the arrangements is as follows:~~

~~Operating Leases~~

~~Lexington~~

~~On September 26, 2016, and as amended on December 31, 2016,~~termination, the Company ~~entered into a~~ ~~10 year and 9-month~~ ~~lease , which includes two successive~~ ~~five-year~~ ~~renewal options~~, for its facility in Lexington, Massachusetts (the “Lexington Lease”), which the Company uses primarily for its current good manufacturing practices (“cGMP”) manufacturing, as well as for additional laboratory and office space. Throughout the term of the Lexington Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. As required under the terms of the Lexington Lease, the Company had restricted cash of approximatelywill recognize $~~2.7~~28.0 million in ~~a separate bank account~~revenue during the three months ended September 30, 2023, this represents the remainder of the deferred revenue for the C9 Target as of June 30, ~~2022 and December 31, 2021.~~

~~Cambridge~~

~~In April 2015, the Company entered into a lease agreement for an office and laboratory facility in Cambridge, Massachusetts (the “Cambridge Lease”), which commenced in October 2015 with a term of~~ ~~7.5~~ ~~years with a~~ ~~five-year~~ ~~renewal~~ ~~option to extend~~ ~~the lease.~~ Throughout the term of the Cambridge Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. As required under the terms of the Cambridge Lease, the Company had restricted cash of $~~1.0~~ ~~million in a separate bank account as of June 30, 2022 and December 31, 2021.~~

In December 2020, the Company exercised its option under the Cambridge Lease to lease additional office and laboratory space at the adjoining facility. The combined space constitutes the entire building located at 733 Concord Avenue. ~~The lease for the additional space commenced on October 1, 2021, with a term of~~ ~~five years~~ ~~and, for accounting purposes, is considered a separate lease from the Cambridge Lease (the “Additional Cambridge Lease”).~~ ~~On the commencement date of the Additional Cambridge Lease, the Company recorded a right-of-use asset and corresponding operating lease liability of $4.5~~ million and began recognizing straight-line rent expense under ASC 842. Throughout the term of the Additional Cambridge Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities.

~~In June 2022, the Company notified the landlord of its intention to exercise the~~ ~~five-year~~ ~~renewal option under the Cambridge Lease to extend the lease term through March 2028 (the “Cambridge Lease Extension”). In June 2022, the Company calculated an incremental borrowing rate of~~ ~~10.53% and remeasured the right-of-use asset and the lease liabilities related to the Cambridge Lease Extension. As of June 30, 2022, the Company recorded an additional $12.0~~ ~~million of operating right-of-use asset and corresponding operating lease liabilities relating to the Cambridge Lease Extension.~~ ~~In August 2022, the Company executed the second amendment to the Cambridge Lease with respect to the Cambridge Lease Extension.~~2023.

1918

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, filed with the Securities and Exchange Commission (“SEC”) on March ~~3, 2022,~~23, 2023, as amended (the ~~“2021~~“2022 Annual Report on Form 10-K”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Quarterly Report on Form 10-Q orand the “Risk Factor” section of our ~~2021~~2022 Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, these forward-looking statements.

Overview

We are a clinical-stage ~~genetic~~RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Using ~~PRISM™,~~PRISM, our proprietary discovery and drug development platform that enables the precise design, optimization, and production of novel stereopure oligonucleotides, we ~~aspire~~are working to develop first- or best-in-class medicines that target the transcriptome (the full set of ribonucleic acid (“RNA”) molecules produced from the human genome) to treat genetically defined diseases with a high degree of unmet need.

WeOur RNA-targeting oligonucleotides are ~~developing oligonucleotides that target ribonucleic acid (“RNA”) and harness existing cellular machinery~~designed to ~~either reduce the expression of disease-promoting RNA or proteins,~~correct disease-causing mutations, modulate protein activity, restore the production of functional proteins or ~~modulate protein expression.~~reduce the expression of disease-promoting RNAs or proteins. Data from our ongoing clinical and preclinical studies has demonstrated significant improvements in potency, durability, and distribution for our oligonucleotides designed through PRISM, compared with competitor chemistries. These data support our platform as best-in-class for designing and optimizing RNA-targeting medicines.

Since our inception, we have seen the value of developing RNA-targeting medicines compared to other nucleic acid therapeutics, including gene therapy and DNA editing. By intervening at the RNA level, we have the potential to address diseases that have historically been difficult to treat with small molecules or biologics, while retaining the ability to titrate dose, modulate duration of effect, and avoid risk of permanent off-target genetic changes and other challenges associated with DNA editing or gene therapy approaches. Oligonucleotides have additional advantages as a therapeutic class, including the ability to access multiple tissue types and the ability to modulate the frequency of dosing to ensure broad distribution within tissues over time. Oligonucleotides also have well-established manufacturing processes and validated test methods based on decades of improvements, as well as established regulatory, access, and reimbursement pathways.

Our approach is based on the scientific insight that the biological machinery necessary to address genetic diseases already exists in human cells and can be ~~controlled~~harnessed for therapeutic purposes with the right tools. We have built a ~~genetic toolkit~~versatile platform comprised of multiple therapeutic modalities, ~~including RNase-H mediated silencing, RNAi, splicing, and RNA base editing, all of~~ which ~~leverage learnings and optimizations from our PRISM platform and allow us~~provides flexibility to design built-for-purpose molecules tothat optimally address disease biology. These modalities are RNA base editing, splicing, and silencing, including both RNA interference (“RNAi”) and antisense, all of which incorporate proprietary and novel chemistries to optimize the pharmacological properties of our therapeutic oligonucleotides.

We have a robust and diverse pipeline of potential first- or best-in-class programs. Our ~~A-to-I(G)~~lead programs are designed to treat genetic diseases, including those in muscle, including Duchenne muscular dystrophy (“DMD”); liver, including alpha-1 antitrypsin deficiency (“AATD”); and the central nervous system (“CNS”), including Huntington’s disease (“HD”). These programs include:

•

WVE-N531 (splicing), our exon 53 molecule for the treatment of DMD;

•

WVE-006 (editing), our SERPINA1 molecule for the treatment of AATD; and

•

WVE-003 (silencing), our mHTT SNP3 molecule for the treatment of HD.

Over the last several years, we have built a leading RNA base editing capability. Our A-to-I RNA base editing oligonucleotides (“AIMers”) ~~represent our newest~~enable access to areas of disease biology that are not viable for other therapeutic ~~modality.~~ modalities. Our editing capability affords us the dexterity to address both rare diseases, as well as diseases impacting large patient populations.

AIMers are designed to ~~edit~~target single ~~base mutations~~bases on an RNA ~~transcripts, thereby avoiding permanent changes to the genome that occur with DNA-targeting approaches. Rather than using an exogenous editing enzyme, AIMers~~transcript and recruit proteins that exist in the body, called ~~“ADAR”~~ADAR (adenosine deaminases acting on RNA) enzymes, which naturally possess the ability to change an adenine (A) to an inosine (I), which cells read as guanine (G). This approach enables both the correction of G-to-A point mutations, as well as the modulation of RNA to upregulate protein expression, modify protein-protein interactions, or alter RNA folding and processing. AIMers enable simplified delivery and ~~avoids~~avoid the risk of permanent changes to the genome and irreversible off-target effects with DNA-targeting approaches. AIMers are short in length, fully chemically modified, and use novel chemistry, including proprietary PN backbone modifications and chiral control, ~~of stereochemistry,~~ which make them distinct from other ADAR-mediated editing approaches.

Our PRISM platform iswas built on the recognition that a significant opportunity exists to tune the pharmacological properties of oligonucleotide therapeutics by leveraging three key features of these molecules: sequence, chemistry, and stereochemistry. Our unique ability to control stereochemistry ~~which is a reality of chemically modified oligonucleotides,~~ provides the resolution necessary to optimize pharmacological ~~profiles.~~

~~PRISM enables us to design~~profiles and develop and manufacture stereopure oligonucleotides. Stereopure oligonucleotides ~~which~~ are comprised of molecules with atoms precisely and purposefully arranged in three-dimensional orientations at each linkage. These differ from the mixture-based oligonucleotides currently on the market or in development by others. Additionally, to mitigate pharmacological risks and potential manufacturing challenges, our approach focuses on designing short, chemically modified oligonucleotides without the need for complex delivery ~~vehicles or engineered exogenous enzymes.~~vehicles. We have also established and continue to enhance our internal current good manufacturing practices (“cGMP”) manufacturing capabilities to increase control and visibility of our drug substance supply chain, while continuing to innovate oligonucleotide manufacturing.

~~Our work in developing stereopure oligonucleotides has enabled the continued evolution of~~ PRISM and our drug discovery process of selecting genetically defined targets, identifying a sequence and applying the therapeutic modality we determine is best suited for the disease biology. We use our PRISM platform engine to screen candidates and optimize the pharmacologic profile based on predefined design principles, which reflect a deep understanding of how the interplay among oligonucleotide sequence, chemistry and backbone stereochemistry impacts key pharmacological properties. Through continued exploration of these interactions using iterative analysis of ~~in vitro~~ ~~and~~ ~~in vivo~~ ~~outcomes and machine learning-driven predictive modeling, we~~ also continue to refine our design principles that we deploy across subsequent programs. We continue to invest in PRISM to further evolve and apply the expanding capabilities and promise of our unique platform.

~~In August 2020, we publicly introduced~~incorporates our novel, proprietary PN backbone chemistry modifications, which have been shown preclinically and clinically to increase potency, distribution, and durability of effect across our various modalities. PN chemistry ~~has been~~is incorporated ~~into~~in all of our current clinical, preclinical and discovery-stage programs.

~~We have~~In December 2022, we announced a ~~robust and diverse pipeline of PN-modified, stereopure oligonucleotides,~~strategic collaboration with GlaxoSmithKline Intellectual Property (No. 3) (“GSK”) to advance transformative oligonucleotide therapeutics, including ~~our clinical silencing and splicing programs,~~WVE-006. The collaboration combines GSK’s unique insights in human genetics, as well as its global development and commercial capabilities, with our ~~AIMers. With RNA base editing,~~PRISM platform and oligonucleotide expertise. The collaboration will enable us to continue building a pipeline of first-in-class oligonucleotide-based therapeutics and unlock new areas of disease biology, as well as realize the full value of WVE-006 as a potential best-in-class treatment for AATD that has the potential to simultaneously address both liver and lung manifestations of the disease.

The GSK collaboration has three components:

(1)

A discovery collaboration which enables us to advance up to three programs leveraging targets informed by GSK’s novel insights;

(2)

A discovery collaboration which enables GSK to advance up to eight programs leveraging PRISM and our ~~initial focus is on using N-acetyl galactosamine (“GalNAc”)-conjugated AIMers~~oligonucleotide expertise and discovery capabilities; and

(3)

An exclusive global license for GSK to ~~treat hepatic diseases. Our lead programs are designed~~WVE-006, our preclinical program for AATD that uses our proprietary AIMer technology. We will maintain development responsibilities for WVE-006 through completion of the first clinical study, at which point development and commercial responsibilities will transition to ~~treat genetic diseases within~~GSK.

On May 23, 2023, we announced topline results from the ~~central nervous system (“CNS”), including~~Phase 1b/2a FOCUS-C9 study and our decision to discontinue clinical development of WVE-004 for C9orf72-associated amyotrophic lateral sclerosis (“ALS”), and frontotemporal dementia (“FTD”)~~, Huntington’s disease~~ (“~~HD”~~C9-ALS/FTD”). Results from the study indicated that WVE-004 was generally safe and well-tolerated across doses of WVE-004, with most adverse events presenting as mild in intensity. Importantly, robust, sustained reductions in poly(GP) dipeptide proteins from baseline were observed in the cerebrospinal fluid (“CSF”), ~~Duchenne muscular dystrophy (“DMD”),~~with a maximal mean reduction of 48% (p<0.0001) in the Q12W dose and ~~alpha-1 antitrypsin deficiency (“AATD”). These programs include:~~

•

50% (p=0.0001) in the Q4W dose of WVE-004, ~~(silencing), our C9orf72-targeted variant selective antisense oligonucleotide for~~successfully translating preclinical model pharmacodynamic effects to clinical biomarker effects. However, no trends in clinical benefit were observed at 24 weeks, and reductions in poly(GP) were not correlated with stabilization or improvement in functional outcomes. Based on these data, and in the ~~treatment~~absence of ~~C9orf72-associated ALS~~biomarkers reasonably likely to predict clinical outcomes, we discontinued development of WVE-004. In July 2023, the joint steering committee that manages the Takeda Collaboration (as defined in Note 5 in the notes to the unaudited consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, “Note 5”) terminated C9-ALS/FTD as a target under the collaboration (the “C9 Target”) and ~~FTD,~~

•

~~WVE-003 (silencing), our SNP3-targeted antisense oligonucleotide for~~consequently Takeda and Wave’s rights and obligations under the ~~treatment of HD, which is designed~~Takeda Collaboration were terminated with respect to ~~selectively lower mutant HTT protein levels, while leaving wild-type HTT protein levels relatively intact,~~

•

~~WVE-N531 (splicing), our exon 53 exon-skipping oligonucleotide for~~ the ~~treatment of DMD, and~~

•C9 Target.

~~WVE-006 (RNA editing), our GalNAc-conjugated SERPINA1 AIMer for the treatment of AATD.~~

When we built Wave, we recognized the growing momentum in RNA therapeutics and anticipated the value in having an internal current good manufacturing practices (“cGMP”) manufacturing facility. This capability provides us with increased control and visibility of our drug substance supply chain, thereby accelerating transitions from discovery through clinical development, and the continued ability to innovate in oligonucleotide manufacturing. Our team includes experts in oligonucleotide manufacturing that have successfully delivered clinical supply for six global studies at Wave to date. With our existing manufacturing facility, we are evaluating using our additional capacity to support the clinical supply of innovative oligonucleotides for new partners.

Our Current Programs

Additional details regarding our lead therapeutic programs are set forth below.

~~Neurology~~Duchenne muscular dystrophy (“DMD”)

~~WVE-004~~: In ~~ALS and FTD,~~DMD, we are advancing ~~WVE-004,~~WVE-N531, which ~~uses~~is designed to skip exon 53 within the dystrophin gene – a therapeutic approach that would address approximately 8-10% of DMD cases. WVE-N531 is designed to cause the cellular splicing machinery to skip over this exon during pre-mRNA processing, which restores the dystrophin mRNA reading frame and enables production of truncated, but functional, dystrophin protein. Exon skipping produces dystrophin from the endogenous dystrophin gene (not micro or mini dystrophin expressed from a vector), under the control of native gene-regulatory elements, resulting in normal expression. WVE-N531 is both our ~~novel~~first splicing candidate and our first systemically administered candidate incorporating PN chemistry ~~and preferentially targets the transcripts containing the hexanucleotide G4C2 expansion~~to be assessed in the clinic.~~C9orf72~~ gene. In C9 BAC transgenic mice, WVE-004 led to substantial reductions in repeat-containing C9orf72 transcripts and dipeptide repeat (“DPR”) proteins that are sustained for at least six months, without disrupting total C9orf72 protein expression.

In 2021, we initiated our FOCUS-C9 trial, which is a global, multicenter, randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial to assess the safety and tolerability of intrathecal doses of WVE-004 for patients with C9-ALS and/or C9-FTD. Additional objectives include measurement of polyGP proteins in the cerebrospinal fluid (“CSF”)December 2022 (data cut-off: December 6, 2022), plasma and CSF pharmacokinetics and exploratory biomarker and clinical endpoints. The FOCUS-C9 trial is designed to be adaptive with dose level and dosing frequency being guided by an independent committee. Preclinical models that have established pharmacologic activity have informed the starting dose for this trial.

~~In April 2022,~~ we announced a positive update from Part A of the Phase 1b/2a proof-of-concept study of WVE-N531 in three boys with DMD amenable to ~~the ongoing FOCUS-C9 trial that was driven by the observation~~exon 53 skipping. High muscle concentrations of potent, durable reductions of poly(GP) dipeptide repeat proteins in CSF with low, single doses of WVE-004. Poly(GP) is a key C9-ALS/C9-FTD disease biomarker that, when reduced in CSF, indicates WVE-004’s engagement of targetWVE-N531 and exon skipping were observed six weeks after initiating biweekly multi-dosing at 10 mg/kg, achieving proof-of-concept in the ~~brain~~study. WVE-N531 also appeared safe and ~~spinal cord. Poly(GP) is also a DPR~~well-tolerated.

To evaluate dystrophin protein ~~translated from both sense and antisense transcripts~~restoration, we are initiating the Phase 2 portion of the ~~C9orf72 repeat expansions responsible for the pathophysiology of disease.~~

•

~~Reductions in poly(GP) were observed across all active treatment groups (10 mg, n=2 patients; 30 mg, n=4 patients; 60 mg, n=3 patients)~~WVE-N531 open-label study (“Part B”), ~~reaching statistical significance versus placebo (n=3 patients) after single 30 mg doses, with a 34% reduction in poly(GP)~~and plan to enroll up to ten boys. Boys will be dosed at ~~day 85 (p=0.011). At the time of analysis, none of the patients dosed with 60 mg had reached day 85.~~

•

~~As the poly(GP) reduction in the 30 mg single dose cohort does not appear to have plateaued,~~10 mg/kg biweekly, and we are extending the observation period from approximately three months (85 days) to approximately six months to identify the maximum reduction of poly(GP) and duration of effect of low single doses. Based on the durability and potency observed in the 30 mg cohort, FOCUS-C9 has been adapted to include additional patients receiving 20 mg and 30 mg single doses of WVE-004.

•

Additional exploratory assessments included monitoring of CSF neurofilament light chain (“NfL”) and clinical outcome measures. CSF NfL elevations were observed in some patients in the 30 mg and 60 mg single dose cohorts with no meaningful changes in clinical outcome measures, although the dataset and duration were not sufficientplan to assess ~~clinical effects. Exploratory assessments~~dystrophin protein after 24 and 48 weeks of dosing. The primary endpoint will ~~continue throughout~~be dystrophin protein levels, and the ~~single~~study will also evaluate pharmacokinetics, functional

endpoints and ~~multidose phases of the FOCUS-C9 trial.~~

•

~~Adverse events were balanced across treatment groups, including placebo,~~safety and were mostly mild to moderate in intensity. Four patients (including one on placebo) experienced severe and/or serious adverse events; three were reported by the investigators to be related to ALS or administration, and one was reported by the investigator to be related to study drug. There were no treatment-associated elevations in CSF white blood cell counts or protein and no other notable laboratory abnormalities were observed.

tolerability. We expect to ~~share additional~~initiate dosing in 2023 and to deliver data in 2024. Based on results from this study, we would consider advancing a broader DMD pipeline with PN-modified splicing oligonucleotides for skipping other exons, with the goal of providing new treatment options for a larger population of boys with DMD.

Alpha-1 antitrypsin deficiency (“AATD”)

Our AATD program is the first to leverage our novel RNA editing capability and uses clinically proven N-acetylgalactosamine (“GalNAc”)-conjugated AIMers with subcutaneous dosing. By correcting the single RNA base mutation that causes a majority of AATD cases with the Pi*ZZ phenotype (approximately 200,000 in the United States and ~~multidose data from~~Europe), RNA editing may provide an ideal approach for increasing circulating levels of wild-type Alpha-1 antitrypsin (“AAT”) protein and reducing mutant protein aggregation in the ~~FOCUS-C9~~liver, thus simultaneously addressing both the lung and liver manifestations of the disease.

In the third quarter of 2022, we announced WVE-006 as our development candidate for AATD. WVE-006 is first-in-class in AATD and is the most advanced program currently in development using an oligonucleotide to harness an endogenous enzyme for RNA editing. IND-enabling studies are complete, and we expect to submit clinical trial applications (CTAs) in the second half of ~~2022. We expect~~2023. Additionally, under the GSK collaboration, GSK received the exclusive global license for WVE-006, with clinical development and commercial responsibilities transitioning to ~~use these data~~GSK after we complete the first clinical trial. Under the terms of the collaboration, we are eligible to ~~optimize dose level~~receive up to $525 million in development, launch and ~~frequency,~~sales-related milestones, as well as ~~enable discussions~~double-digit tiered royalties as a percentage of net sales up to the high teens, for WVE-006.

Preclinical data show that treatment with ~~regulatory authorities regarding~~WVE-006 resulted in approximately 50% RNA editing of SERPINA1 transcript and approximately 7-fold greater AAT protein levels (well above the ~~next phase~~predicted protective threshold of ~~development later~~11uM) at 13 weeks in ~~2022. Planning is underway for expected initiation~~an established AATD mouse model (NSG-PiZ). WVE-006 also led to restoration of ~~an open-label extension clinical trial~~approximately 50% wild-type M-AAT protein in serum and a 3-fold increase in neutrophil elastase inhibition activity, indicating that the restored M-AAT protein was functional. Wave’s AATD AIMers are highly specific to SERPINA1 RNA in vitro and in vivo based on transcriptome-wide analyses.

If we are successful in the ~~second half~~clinic with WVE-006, we will both validate our clinical approach to AATD, as well as validate the feasibility of ~~2022.~~RNA editing in humans.

23Huntington’s disease (“HD”)

~~WVE-003~~: In HD, we are currently advancing WVE-003, a stereopure antisense oligonucleotide designed to selectively target an undisclosed single nucleotide polymorphism (“SNP”), “mHTT SNP3”, associated with the disease-causing mutant huntingtin (“mHTT”) mRNA transcript within the ~~HTT~~Huntingtin(“HTT”) gene. Approximately 40% of the HD population carries SNP3 according to published literature (Carroll et al., Molecular Therapy, 2011).

WVE-003 incorporates our novel PN chemistry, as well as learnings from our first-generation HD programs. Targeting mRNA with SNP3 allows us to lower expression of transcript from the mutant allele, while leaving the healthy transcript relatively intact, thereby preserving wild-type (healthy) huntingtin (“wtHTT”) protein, which is important for neuronal function. Our allele-selective approach may also enable us to address the pre-manifest, or asymptomatic, HD patient population in the future. In preclinical studies, WVE-003 showed dose-dependent and selective reduction of mHTT mRNA in vitro ~~and~~, as well as potent and durable knockdown of mHTT mRNA and protein in vivo~~. A pharmacokinetic-pharmacodynamic (“PK-PD”) model for WVE-003 based on preclinical data predicts that WVE-003 may attain sufficient concentrations to engage mHTT transcript~~ in ~~both the cortex and striatum and decrease expression of the mHTT protein.~~mouse models.

The SELECT-HD trial is a multicenter, randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial to assess the safety and tolerability of intrathecally administered WVE-003 for patients with early manifest HD. Additional objectives include measurement of mHTT and wtHTT protein and exploratory pharmacokinetic, pharmacodynamic, clinical and magnetic resonance imaging (“MRI”) endpoints. The SELECT-HD trial is designed to be adaptive, with dose level and dosing frequency being guided by an independent committee. ~~Preclinical models that have established pharmacologic activity have informed the starting dose for this trial.~~

In September ~~2021,~~2022 (data cut-off: August 29, 2022), we announced a positive update from SELECT-HD driven by the ~~initiation~~observation of ~~dosing~~reductions in mHTT protein in cerebrospinal fluid (“CSF”) after study participants received either a single 30 or 60 mg dose of WVE-003. Additionally, wtHTT protein levels appeared consistent with allele-selectivity. Single doses (30 mg, 60 mg, and 90 mg) of WVE-003 appeared generally safe and well-tolerated. Based on the SELECT-HD ~~trial. We~~data, we adapted the trial to expand the single-dose cohorts, the multi-dose portion is underway, and we expect to share ~~clinical~~additional single-dose, as well as available multi-dose, biomarker and safety data in the second half of ~~2022 to provide further insight into~~2023. As previously disclosed, Wave’s mHTT assay vendor experienced a cyber-attack in April 2023. No Wave data or patient samples were impacted by the ~~clinical effects of PN chemistry~~attack and ~~enable decision making for WVE-003.~~Wave remains in close contact with the vendor as they address this issue.

~~WVE-N531~~: In DMD, we are advancing WVE-N531, which is designed to target exon 53 within the dystrophin gene. WVE-N531 is designed to cause the cellular splicing machinery to skip over this exon during pre-mRNA processing, which restores the dystrophin mRNA reading frame and enables production of truncated, but functional dystrophin protein. Exon-skipping produces dystrophin from the endogenous dystrophin gene (not micro or mini dystrophin expressed from a vector), under the control of native gene-regulatory elements, resulting in normal temporospatial expression. WVE-N531 is both our first splicing candidate and our first systemically administered candidate incorporating PN chemistry to be assessed in the clinic.

In September 2021, we announced the initiation of dosing in an open-label clinical trial evaluating WVE-N531 as a treatment for boys with DMD who are amenable to exon 53 skipping. We expect to share clinical data, including muscle biopsies, in the fourth quarter of 2022 to provide further insight into the clinical effects of PN chemistry and enable decision making for WVE-N531.

~~Hepatic~~Discovery Pipeline

We are ~~initially focused~~advancing new targets across multiple disease areas, in light of compelling preclinical data indicating our oligonucleotides can distribute to various tissues and cells without complex delivery vehicles. We are also focusing on ~~developing AIMers (A-to-I(G) RNA base editing oligonucleotides), which use~~targets that have been genetically

validated and offer biomarkers for target engagement to enable early proof-of-concept in the clinic. We expect this research to result in multiple new programs with first-in-class potential being added to our pipeline over the next several years.

In April 2023, we announced the publication of preclinical data for our novel PN chemistry, to address genetic hepatic diseases. Our AIMers are relatively short and stable (fully chemically modified), which enables us to leverage clinically-proven GalNAc-mediated delivery to hepatocytes with subcutaneous dosing.

~~WVE-006:~~ In AATD, we are currently advancing WVE-006, our first AIMer (RNA editing) candidate that uses GalNAc-conjugation and endogenous ADAR enzymes to correct the SERPINA1 Z mutation, which is the most common cause of AATD. ADAR editing may provide an ideal approach for increasing circulating levels of wild-type AAT protein and reducing aggregationsiRNA formats in the ~~liver, thus simultaneously addressing both the lung~~journal of Nucleic Acids Research. The preclinical data demonstrated unprecedented Ago2 loading following administration of single subcutaneous GalNAc-siRNA dose, leading to improved potency and ~~liver manifestations of the disease. We selected WVE-006 as our AATD AIMer development candidate, our IND-enabling activities are underway, and we expect to submit clinical trial applications~~ durability in ~~2023.~~vivo

~~Continuing Impacts of COVID-19~~ versus comparator siRNA formats.

We ~~continue to closely monitor developments related to COVID-19, which was declared a pandemic by~~have also demonstrated the ~~World Health Organization on March 11, 2020. In response to this global pandemic, we have concentrated our efforts on the health and safety~~potential of our ~~employees and patients, while maintaining business continuity and honoring~~siRNA to silence targets in extra-hepatic tissues. In the first quarter of 2023, we announced data from our ~~commitment to deliver life-changing treatments for people battling devastating diseases.~~first in vivo siRNA study in the central nervous system (CNS), where our unconjugated siRNA constructs demonstrated 70-90% APP silencing across six brain regions in mouse CNS at eight weeks, following a single intracerebroventricular (ICV) dose.

~~Our on-site activities continue~~Through our collaboration with ~~protocols~~GSK, we are gaining access to proprietary genetic insights to expand our wholly-owned pipeline. In addition, we and GSK are actively working on multiple target validation programs for ~~safely accessing and working within~~ our facilities, including a mandatory COVID-19 vaccination policy that we implemented in October 2021. While we continue to conduct research and development activities, including our ongoing clinical trials, the COVID-19 pandemic has impacted, and may continue to impact, certainGSK-partnered programs, for which all of our ~~early-stage discovery efforts~~costs and ~~clinical trials. We~~expenses are working with our clinical investigators, research and development vendors, and supply chain vendors to continually assess and take steps to mitigate the potential impact of COVID-19 on our manufacturing operations and research and development activities.prepaid by GSK.

We will continue to closely monitor the COVID-19 situation as we evolve our business continuity plans. Given the global risks and uncertainties associated with COVID-19, our business, results of operations, and prospects could be materially adversely affected. For additional information, see “Item 1A. Risk Factors” in the 2021 Annual Report on Form 10-K.

Financial Operations Overview

We have never been profitable, and since our inception, we have incurred significant operating losses. Our net loss ~~was $41.3 million and $38.8 million~~ for the three months ended June 30, 2023 and 2022 was $21.1 million and ~~2021,~~$41.3 million, respectively. Our net loss ~~was $79.1 million and $81.2 million~~ for the six months ended June 30, 2023 and 2022 was $48.5 million and ~~2021,~~$79.1 million, respectively. As of June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, we had an accumulated deficit of ~~$884.6~~$1,015.8 million and ~~$805.5~~$967.3 million, respectively. We expect to continue to incur significant expenses and operating losses for the foreseeable future.

Revenue

We recognize collaboration revenue under the GSK Collaboration Agreement, which became effective in January 2023 (as defined in Note 5), and the Takeda Collaboration Agreement (as defined in Note 5), which became effective in April 2018. We have not generated any product revenue since our inception and do not expect to generate any revenue from the sale of products for the foreseeable future. Under the revenue recognition standard, we recognize collaboration revenue under the Takeda Collaboration Agreement (as defined in Note 5 in the notes to the unaudited consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, “Note 5”), which became effective in April 2018.

Operating Expenses

Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative expenses.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, which include:

•

compensation-related expenses, including employee salaries, bonuses, share-based compensation expense and other related benefits expenses for personnel in our research and development organization;

•

expenses incurred under agreements with third parties, including contract research organizations (“CROs”) that conduct research, preclinical and clinical activities on our behalf, as well as contract manufacturing organizations (“CMOs”) that manufacture drug product for use in our preclinical studies and clinical trials;

•

expenses incurred related to our internal manufacturing of drug substance for use in our preclinical studies and clinical trials;

•

expenses related to compliance with regulatory requirements;

•

expenses related to third-party consultants;

•

research and development supplies and services expenses; and

•

facility-related expenses, including rent, maintenance and other general operating expenses.

We recognize research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued expenses.

Our primary research and development focus since inception has been the development of our proprietary discovery and drug development platform, PRISM. We are using PRISM, which includes our novel PN backbone chemistry modifications, to design,

develop and commercialize a broad pipeline of nucleic acid therapeutic candidates that target RNA using ~~silencing,~~RNA editing, splicing, and ~~ADAR editing.~~silencing.

Our research and development expenses consist primarily of expenses related to our CROs, CMOs, consultants, other external vendors and fees paid to global regulatory agencies to conduct our clinical trials, in addition to compensation-related expenses, internal manufacturing expenses, facility-related expenses and other general operating expenses. These expenses are incurred in connection with research and development efforts and our preclinical studies and clinical trials. We track certain external expenses on a program-by-program basis. However, we do not allocate compensation-related expenses, internal manufacturing expenses, equipment repairs and maintenance expense, facility-related expenses or other operating expenses to specific programs. These expenses, which are not allocated on a program-by-program basis, are included in the “PRISM and other research and development expenses” category along with other external expenses related to our discovery and development programs, as well as platform development and identification of potential drug discovery candidates.

Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect to continue to incur significant research and development expenses in the foreseeable future as we continue to manage our existing clinical trials, initiate additional clinical trials for certain product candidates, pursue later stages of clinical development for certain product candidates, maintain our manufacturing capabilities and continue to discover and develop additional product candidates in multiple therapeutic areas.

General and Administrative Expenses

General and administrative expenses consist primarily of compensation-related expenses, including salaries, bonuses, share-based compensation and other related benefits costs for personnel in our executive, finance, corporate, legal and administrative functions, as well as compensation-related expenses for our board of directors. General and administrative expenses also include legal fees; expenses associated with being a public company; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; other operating costs; and facility-related expenses.

Other Income, Net

Other income, net ~~consists~~is comprised primarily of dividend income and refundable tax credits from tax authorities. We recognize refundable tax credits when there is reasonable assurance that we will comply with the requirements of the refundable tax credit and that the refundable tax credit will be received.

Income Taxes

We are a Singapore multi-national company subject to taxation in the United States and various other jurisdictions.

Critical Accounting Policies and Significant Judgments and Estimates

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United ~~States.~~States of America. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures.

~~Our significant~~ Management considers many factors in selecting appropriate financial accounting policies ~~judgments~~ and in developing the estimates and assumptions that are ~~described in Note 2~~used in the ~~notes to~~preparation of the ~~audited consolidated~~ financial ~~statements included in the 2021 Annual Report on Form 10-K, as well as in Note 2 in the notes to the unaudited consolidated financial statements included~~statements. Management must apply significant judgment in this ~~Quarterly Report on Form 10-Q.~~process. We believe that our revenue recognition policy, particularly (a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in our analysis of contracts with CROs and CMOs to estimate the contract expense, involve a greater degree of judgment, and therefore we consider them to be our critical accounting policies. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.

2624

Results of Operations

Comparison of the three months ended June 30, ~~2022~~2023 and ~~2021~~2022


	Three Months Ended June 30,
	2023			2022			Change
	(in thousands)
Revenue	$	22,106		$	375		$	21,731
Operating expenses:
Research and development		33,314			29,733			3,581
General and administrative		12,265			12,806			(541	)
Total operating expenses		45,579			42,539			3,040
Loss from operations		(23,473	)		(42,164	)		18,691
Total other income, net		2,369			868			1,501
Loss before income taxes		(21,104	)		(41,296	)		20,192
Income tax provision		—			—			—
Net loss	$	(21,104	)	$	(41,296	)	$	20,192

Three Months Ended June 30,

2022

2021

Change

(in thousands)

Revenue

$
375

$
2,776

$
(2,401
)
Operating expenses:

Research and development

29,733

31,635

(1,902
)
General and administrative

12,806

10,969

1,837

Total operating expenses

42,539

42,604

(65
)
Loss from operations

(42,164
)

(39,828
)

(2,336
)
Total other income, net

868

1,062

(194
)
Loss before income taxes

(41,296
)

(38,766
)

(2,530
)
Income tax provision

—

—

—

Net loss

$
(41,296
)

$
(38,766
)

$
(2,530
)

Revenue

Revenue for the three months ended June 30, ~~2022~~2023 was $22.1 million and ~~2021~~was earned under the GSK Collaboration Agreement and the Takeda Collaboration Agreement. Revenue for the three months ended June 30, 2022 was $0.4 million and ~~$2.8 million, respectively, and~~ was ~~primarily~~ earned ~~under the Takeda Collaboration Agreement. The decrease in revenue is driven by an increase in the expected future research and development services~~primarily under the Takeda Collaboration Agreement, ~~based on~~as the GSK Collaboration Agreement became effective in January 2023. The year-over-year increase is primarily driven by the revenue ~~recognition standard, as well as~~earned under the ~~discontinuation of the Category 2 component in the third quarter of 2021.~~GSK Collaboration Agreement.

Research and Development Expenses


	Three Months Ended June 30,							Three Months Ended June 30,
	2022		2021		Change			2023		2022		Change
	(in thousands)							(in thousands)
ALS and FTD program	$	3,348	$	3,381	$	(33	)	$	3,334	$	3,348	$	(14	)
HD programs		1,253		6,911		(5,658	)		4,095		1,253		2,842
DMD programs		392		356		36			2,255		392		1,863
AATD program		1,541		3		1,538			2,156		1,541		615
PRISM and other research and development expenses (1)		23,199		20,984		2,215			21,474		23,199		(1,725	)
Total research and development expenses	$	29,733	$	31,635	$	(1,902	)	$	33,314	$	29,733	$	3,581

(1)

Includes expenses related to discovery and development programs, identification of potential drug discovery candidates, compensation, internal manufacturing, equipment repairs and maintenance, facilities and other operating expenses, which are not allocated to specific programs.

Research and development expenses were $33.3 million for the three months ended June 30, 2023, compared to $29.7 million for the three months ended June 30, ~~2022, compared to approximately $31.6 million for the three months ended June 30, 2021.~~2022. The ~~decrease~~increase of ~~$1.9~~$3.6 million was due to the following:

•

a ~~decrease of~~ less than $0.1 million decrease in external expenses related to our ALS and FTD program, WVE-004 (PN-modified silencing oligonucleotide);, which we discontinued in May 2023;

•

~~a decrease~~an increase of ~~$5.7~~$2.8 million in external expenses related to our HD programs, ~~driven by decreased external expenses related to our discontinued WVE-120101 and WVE-120102 programs, partially offset by continuing external expenses for~~including our WVE-003 (PN-modified silencing oligonucleotide) program;

•

an increase of ~~less than $0.1~~$1.9 million in external expenses related to our DMD programs, including WVE-N531 (PN-modified splicing oligonucleotide);

•

an increase of ~~$1.5~~$0.6 million in external expenses related to our AATD program, WVE-006 (PN-modified RNA editing oligonucleotide); and

•

~~an increase~~a decrease of ~~$2.2~~$1.7 million in internal and external research and development expenses that are not allocated on a program-by-program basis and are related to other discovery and development programs, including PRISM and the identification of potential drug discovery candidates, ~~primarily~~mainly due to ~~increases in compensation-related expenses,~~

~~including the share-based compensation expense related to the achievement of a performance-based RSU milestone, offset by~~ decreases in ~~other~~ external research and development expenses and compensation-related expenses, partially offset by increases in facilities-related expenses.

General and Administrative Expenses

General and administrative expenses were $12.3 million for the three months ended June 30, 2023, as compared to $12.8 million for the three months ended June 30, ~~2022, as compared to $11.0 million for the three months ended June 30, 2021.~~2022. The ~~increase of $1.8 million~~decrease is primarily driven by ~~increases~~decreases in compensation-related expenses, ~~including the share-based compensation expense related to the achievement of a performance-based RSU milestone,~~partially offset by ~~decreases~~increases in other external general and administrative expenses and facilities-related expenses.

Other Income, Net

Other income, net for the three months ended June 30, 2023 and 2022 was $2.4 million and ~~2021, was~~ $0.9 million, respectively, and ~~$1.1 million, respectively. Other income, net for both periods primarily~~ consisted of dividend income ~~related to~~and estimated refundable tax ~~credits from tax authorities.~~credits. The increase in other income year-over-year was driven by an increase in dividend income.

Income Tax Provision

During the three months ended June 30, ~~2022~~2023 and ~~2021,~~2022, we recorded no income tax provision. We maintained a full valuation allowance for the three months ended June 30, ~~2022~~2023 and ~~2021~~2022 in all jurisdictions due to uncertainty regarding future taxable income.

Comparison of the six months ended June 30, ~~2022~~2023 and ~~2021~~2022


	Six Months Ended June 30,									Six Months Ended June 30,
	2022			2021			Change			2023			2022			Change
	(in thousands)									(in thousands)
Revenue	$	2,125		$	2,776		$	(651	)	$	35,035		$	2,125		$	32,910
Operating expenses:
Research and development		57,203			65,028			(7,825	)		64,293			57,203			7,090
General and administrative		25,180			21,047			4,133			24,500			25,180			(680	)
Total operating expenses		82,383			86,075			(3,692	)		88,793			82,383			6,410
Loss from operations		(80,258	)		(83,299	)		3,041			(53,758	)		(80,258	)		26,500
Total other income, net		1,148			2,069			(921	)		5,249			1,148			4,101
Loss before income taxes		(79,110	)		(81,230	)		2,120			(48,509	)		(79,110	)		30,601
Income tax provision		—			—			—			—			—			—
Net loss	$	(79,110	)	$	(81,230	)	$	2,120		$	(48,509	)	$	(79,110	)	$	30,601

Revenue

Revenue for six months ended June 30, 2023 was $35.0 million and was earned under the GSK Collaboration Agreement and the Takeda Collaboration Agreement. Revenue for six months ended June 30, 2022 ~~and 2021~~ was $2.1 million ~~and $2.8 million, respectively,~~ and was primarily earned under the Takeda Collaboration ~~Agreement.~~Agreement, as the GSK Collaboration Agreement became effective in January 2023. The ~~decrease in revenue~~year-over-year increase is primarily driven by the ~~discontinuation of~~revenue earned under the ~~Category 2 component in the third quarter of 2021.~~GSK Collaboration Agreement.

2826

Research and Development Expenses


	Six Months Ended June 30,							Six Months Ended June 30,
	2022		2021		Change			2023		2022		Change
	(in thousands)							(in thousands)
ALS and FTD program	$	5,087	$	6,821	$	(1,734	)	$	6,051	$	5,087	$	964
HD programs		3,446		15,361		(11,915	)		7,417		3,446		3,971
DMD programs		817		156		661			2,569		817		1,752
AATD program		1,852		3		1,849			3,724		1,852		1,872
PRISM and other research and development expenses (1)		46,001		42,687		3,314			44,532		46,001		(1,469	)
Total research and development expenses	$	57,203	$	65,028	$	(7,825	)	$	64,293	$	57,203	$	7,090

(1)

Research and development expenses were $64.3 million for the six months ended June 30, 2023, compared to $57.2 million for the six months ended June 30, ~~2022, compared to $65.0 million for the six months ended June 30, 2021.~~2022. The ~~decrease~~increase of ~~$7.8~~$7.1 million was due to the following:

•

~~a decrease~~an increase of ~~$1.7~~$1.0 million in external expenses related to our ALS and FTD program, WVE-004 (PN-modified silencing oligonucleotide);, which we discontinued in May 2023;

•

~~a decrease~~an increase of ~~$11.9~~$4.0 million in external expenses related to our HD programs, driven by decreased external expenses related to our discontinued WVE-120101 and WVE-120102 programs, partially offset by continuing external expenses for our WVE-003 (PN-modified silencing oligonucleotide) program;

•

an increase of ~~$0.7~~$1.8 million in external expenses related to our DMD programs, including WVE-N531 (PN-modified splicing oligonucleotide);

•

an increase of ~~$1.8~~$1.9 million in external expenses related to our AATD program, WVE-006 (PN-modified RNA editing oligonucleotide); and

•

~~an increase~~a decrease of ~~$3.3~~$1.5 million in internal and external research and development expenses that are not allocated on a program-by-program basis and are related to other discovery and development programs, including PRISM and the identification of potential drug discovery candidates, primarily due to ~~increases~~decreases in external research and development expenses and depreciation expenses, partially offset by increased compensation-related expenses ~~including the share-based compensation expense~~and facilities related ~~to the achievement of a performance-based RSU milestone.~~expenses.

General and Administrative Expenses

General and administrative expenses were $24.5 million for the six months ended June 30, 2023, as compared to approximately $25.2 million for the six months ended June 30, ~~2022, as compared to approximately $21.0 million for the six months ended June 30, 2021.~~2022. The ~~increase~~decrease of ~~$4.1~~$0.7 million was primarily due to ~~increases~~decreases in compensation-related expenses, ~~including the share-based compensation expense related to the achievement of a performance-based RSU milestone, as well as increases in professional services expenses and other~~partially offset by increased external general and administrative ~~operating~~expenses and facilities related expenses.

Other Income (Expense), Net

Other income, net for the six months ended June 30, ~~2022~~2023 was $5.2 million and ~~2021,~~consisted primarily of dividend income, as well as estimated refundable tax credits. Other income, net for the six months ended June 30, 2022 was $1.1 million and ~~$2.1 million, respectively. Other income, net for both periods~~ primarily ~~consisted of income~~ related to estimated refundable tax ~~credits from tax authorities.~~credits. The increase year-over-year was driven by the increase in dividend income.

Income Tax Provision

During the six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, we recorded no income tax provision. We maintained a full valuation allowance for the six months ended June 30, ~~2022~~2023 and ~~2021~~2022 in all jurisdictions due to uncertainty regarding future taxable income.

Liquidity and Capital Resources

Since our inception, we have not generated any product revenue and have incurred recurring net losses. To date, we have primarily funded our operations through public and other registered offerings of our ordinary shares, collaborations with third parties and private placements of debt and equity securities. Through June 30, ~~2022,~~2023, we have received an aggregate of approximately ~~$1,021.2~~$1,192.9 million in net proceeds from these transactions, consisting of ~~$630.9~~$632.6 million in net proceeds from public and other registered offerings of our ordinary shares, ~~$301.0~~$471.0 million from our collaborations and $89.3 million in net proceeds from private placements of our debt and equity securities.

On June 16, 2022, we closed an underwritten offering (the “June 2022 Offering”), in which we issued and sold 25,464,483 ordinary shares and Pre-Funded Warrants to purchase up to 7,093,656 ordinary shares. The net proceeds of the June 2022 Offering were approximately $65.5 million.

As of June 30, ~~2022,~~2023, we had cash and cash equivalents ~~and short-term investments~~ totaling ~~$148.2~~$173.0 million, restricted cash of $3.7 million ~~for our leased premises in Cambridge, Massachusetts and Lexington, Massachusetts,~~ and an accumulated deficit of ~~$884.6~~$1,015.8 million. ~~Our operating lease commitments as of June 30, 2022 total approximately $50.6 million, of which $3.6 million is related to payments in 2022 and $47.0 million is related to payments beyond 2022.~~

We expect that our existing cash and cash equivalents ~~and short-term investments~~ will be sufficient to fund our operations for at least the next twelve months. We have based this expectation on assumptions that may prove to be incorrect, and we may use our available capital resources sooner than we currently expect. In addition, we may elect to raise additional funds before we need them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if we expect we have sufficient funds for our current or future operating plans.

Our operating lease commitments as of June 30, 2023 total approximately $42.2 million, of which $3.8 million is related to payments in 2023 and $38.4 million is related to payments beyond 2023.

Until we can generate significant revenue from product sales, if ever, we expect to continue to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. In May 2019, we filed a shelf registration statement on Form S-3ASR with the SEC pursuant to which we registered for sale an indeterminate amount of any combination of our ordinary shares, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine. Our shelf registration statement on Form S-3ASR also included a prospectus covering up to an aggregate of $250.0 million in ordinary shares that we may issue and sell from time to time, through Jefferies LLC (“Jefferies”) acting as our sales agent, pursuant to the open market sales agreement that we entered into with Jefferies in May 2019, as amended in March 2020 and March 2022 ~~(the~~(as amended, the “Sales Agreement”), for our “at-the-market” equity program. Since we no longer qualified as a “well-known seasoned issuer” at the time of the filing of our Annual Report on Form 10-K for the year ended December 31, 2019, we previously amended the shelf registration statement to register for sale up to $500.0 million of any combination of our ordinary shares, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine, including the $250.0 million in ordinary shares that we may issue and sell from time to time pursuant to our “at-the-market” equity program. This registration statement, which we refer to as the “2019 Form S-3,” remained effective until our 2022 Form S-3 (as defined below) was declared effective on May 4, 2022, after which time we may no longer offer or sell any securities under the 2019 Form S-3. During the ~~six~~three months ended June 30, ~~2022, the Company~~2023, we sold ~~458,092~~429,051 ordinary shares under ~~its~~our at-the-market equity program for aggregate ~~net~~gross proceeds of ~~$1.2~~$1.9 million.

On March 3, 2022, we filed a new universal shelf registration on Form S-3 with the SEC, which was declared effective by the SEC on May 4, 2022, pursuant to which we registered for sale up to $500.0 million of any combination of our ordinary shares, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine, which we refer to as the “2022 Form S-3.” The 2022 Form S-3 includes a prospectus covering up to approximately $132.0 million in ordinary shares that ~~have~~had not yet been issued or sold under our Sales Agreement with Jefferies. As of ~~August 10, 2022,~~June 30, 2023, we have ~~$430.0~~$428.1 million in securities available for issuance under the 2022 Form S-3, including approximately ~~$132.0~~$130.1 million in ordinary shares available for issuance under our at-the-market equity program.

Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.

3028

Cash Flows

The following table summarizes our cash flow activity:


	Six Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2023			2022
	(in thousands)						(in thousands)
Net cash used in operating activities	$	(68,695	)	$	(53,776	)
Net cash provided by (used in) operating activities							$	48,265		$	(68,695	)
Net cash used in investing activities		(25,594	)		(447	)		(561	)		(25,594	)
Net cash provided by financing activities		67,116			13,686			36,902			67,116
Effect of foreign exchange rates on cash, cash equivalents and restricted cash		(228	)		(120	)		(121	)		(228	)
Net decrease in cash, cash equivalents and restricted cash	$	(27,401	)	$	(40,657	)
Net increase (decrease) in cash, cash equivalents and restricted cash							$	84,485		$	(27,401	)

Operating Activities

During the six months ended June 30, 2023, operating activities provided $48.3 million of cash, due to our net loss of $48.5 million, offset by non-cash charges of $9.9 million and changes in operating assets and liabilities of $86.9 million. The largest change in operating assets and liabilities was a $104.3 million increase in deferred revenue, mainly driven by our GSK Collaboration Agreement, which became effective in January 2023.

During the six months ended June 30, 2022, operating activities used $68.7 million of cash, primarily due to our net loss of $79.1 million, offset by $10.9 million of share-based compensation expense.

Investing Activities

During the six months ended June 30, ~~2021, operating~~2023, investing activities used ~~$53.8~~$0.6 million of cash, ~~primarily due~~related to ~~our net loss~~purchases of ~~$81.2 million, offset by a $30.0 million decrease in accounts receivable.~~

~~Investing Activities~~property and equipment.

During the six months ended June 30, 2022, investing activities used $25.6 million of cash, of which $50.0 million related to purchases of short-term investments, $25.0 million of which was subsequently sold, and $0.6 million related to purchases and sales of property and equipment.

Financing Activities

During the six months ended June 30, ~~2021, investing~~2023, net cash provided by financing activities ~~used $0.4~~was $36.9 million, ~~of cash, related~~which was primarily due to ~~purchases of property and equipment.~~

~~Financing Activities~~the GSK Equity Investment (as defined in Note 5).

During the six months ended June 30, 2022, net cash provided by financing activities was $67.1 million, which was primarily due to the net proceeds from ~~the~~our previously disclosed June 2022 ~~Offering,~~underwritten offering, which was comprised of sales of ordinary shares and Pre-Funded Warrants.

During the six months ended June 30, 2021, net cash provided by financing activities was $13.7 million, which was primarily due to the net proceeds from sales of ordinary shares under our at-the-market equity program.

Funding Requirements

We expect to continue to incur significant expenses in connection with our ongoing research and development activities and our internal cGMP manufacturing activities. Furthermore, we anticipate that our expenses will continue to vary if and as we:

•

continue to conduct our clinical trials evaluating our product candidates in patients;

•

conduct research and preclinical development of discovery targets and advance additional programs into clinical development;

•

file clinical trial applications with global regulatory agencies and conduct clinical trials for our programs;

•

~~evaluate next steps for our programs in rare, inherited eye diseases;~~

•

make strategic investments in continuing to innovate our research and development platform, PRISM, and in optimizing our manufacturing processes and formulations;

•

maintain our manufacturing capabilities through our internal facility and our CMOs;

•

maintain our intellectual property portfolio and consider the acquisition of complementary intellectual property;

•

seek and obtain regulatory approvals for our product candidates;

•

respond to the impacts of the COVID-19 global pandemic, the conflict involving Russia and Ukraine, global economic uncertainty, rising inflation, rising interest rates or market disruptions on our business; and

•

establish and build capabilities to market, distribute and sell our product candidates.

3129

We may experience delays or encounter issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.

Because of the numerous risks and uncertainties associated with the development of drug candidates and because the extent to which we may enter into collaborations with third parties for development of product candidates is unknown, we are unable to estimate the amounts of future capital outlays and operating expenses associated with completing the research and development for our therapeutic programs. Our future capital requirements for our therapeutic programs will depend on many factors, including:

•

the progress, results and costs of conducting research and continued preclinical and clinical development for our therapeutic programs and future potential pipeline candidates;

•

the number and characteristics of product candidates and programs that we pursue;

•

the cost of manufacturing clinical supplies of our product candidates;

•

whether and to what extent milestone events are achieved under our ~~collaboration~~collaborations with Takeda and GSK or any potential future licensee or collaborator;

•

the costs, timing and outcome of regulatory review of our product candidates;

•

our ability to obtain marketing approval for our product candidates;

•

the impacts of the COVID-19 global pandemic, the conflict involving Russia and Ukraine, global economic uncertainty, rising inflation, rising interest rates or market disruptions on our business;

•

the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;

•

market acceptance of our product candidates, to the extent any are approved for commercial sale, and the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;

•

the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;

•

the effect of competing technological and market developments; and

•

the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates.

Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.

Adequate additional funds may not be available to us on acceptable terms when we need them, or at all. We do not currently have any committed external source of funds, except for possible future payments from Takeda or GSK under ~~the Takeda Collaboration Agreement.~~our collaborations with them. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing shareholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our shareholders. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute our shareholders’ ownership interests.

If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

3230

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates and foreign exchange rates, as well as, to a lesser extent, inflation and capital market risk.

Interest Rate Risk

We are exposed to interest rate risk in the ordinary course of our business. Our cash and cash equivalents are comprised of funds held in ~~readily available~~ checking accounts and money market accounts. ~~Our short-term investments are comprised of term deposits which have fixed interest rates.~~

Foreign Currency ~~Exchange Rate~~ Risk

Due to our operations outside of the United States, we are exposed to market risk related to changes in foreign currency exchange rates. Historically, we have not hedged our foreign currency exposure. Changes in the relative values of currencies occur regularly and, in some instances, could materially adversely affect our business, our financial conditions, our results of operations or our cash flows. For the three and six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, changes in foreign currency exchange rates did not have a material impact on our historical financial position, our business, our financial condition, our results of operations or our cash flows.

Inflation Risk

We do not believe that inflation had a material effect on our business, financial condition, results of operations or cash flows ~~for~~in the ~~three and six months ended June 30, 2022 and 2021.~~last two years. If ~~the~~ global ~~inflationary~~inflation trends continue, we expect appreciable increases in clinical trial, labor, and other operating costs.

Capital Market Risk

We currently have no product revenues and depend on funds raised through other sources. One possible source of funding is through further equity offerings. Our ability to raise funds in this manner depends upon capital market forces affecting our share price, including impacts of ~~the COVID-19 pandemic~~global economic uncertainty on the capital markets.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, ~~2022.~~2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the ~~Securities~~ Exchange Act, ~~of 1934, as amended (the “Exchange Act”),~~ means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, ~~2022,~~2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended June 30, ~~2022~~2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3331

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently a party to any material legal proceedings.

Item 1A. Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, ~~including the risk factor below,~~ you should carefully consider the factors discussed under the caption “Risk Factors” that appear in Item 1A of our ~~2021~~2022 Annual Report on Form 10-K.

~~We issued pre-funded warrants as part of our June 2022 financing, which may cause additional dilution to our shareholders.~~

In June 2022, we closed an underwritten offering in which we issued and sold 25,464,483 ordinary shares and, to RA Capital Management, L.P. in lieu of additional ordinary shares, pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 7,093,656 ordinary shares at an exercise price of $0.0001 per share. The Pre-Funded Warrants contain a so-called “blocker” provision which provides that they are only exercisable upon receipt of shareholder approval or if such exercise would not cause the aggregate number of ordinary shares or the combined voting power of total securities, in each case, beneficially owned by the holder (together with its affiliates) to exceed 19.99% of the number of ordinary shares or total securities, respectively, outstanding immediately after giving effect to the exercise. To the extent the Pre-Funded Warrants above are exercised, additional ordinary shares will be issued and such issuance would dilute existing shareholders and increase the number of shares eligible for resale in the public market.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Equity Securities

None.

Issuer Purchases of Equity Securities

We did not repurchase any of our equity securities during the three months ended June 30, ~~2022.~~2023.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

The information set forth in this paragraph is included herein for the purpose of providing the disclosure required under “Item 1.01 - Entry into a Material Definitive Agreement” of Form 8-K. On August 8, 2022, Wave Life Sciences USA, Inc. (the “Subsidiary”), a wholly-owned subsidiary of Wave Life Sciences Ltd. (and together with the Subsidiary, the “Company”), entered into the Second Amendment to its lease with CPI/King 733 Concord Owner, LLC (the “Second Lease Amendment”), which, among other things, extended the term of the lease at 733 Concord Avenue, Cambridge, Massachusetts, which serves as the Company’s U.S. headquarters. The Second Lease Amendment amends the lease agreement dated as of April 6, 2015, between the Subsidiary and King 733 Concord LLC, an affiliate of King Street Properties Investments, LLC (the “Original Lease”), as amended by the First Amendment to the Original Lease dated December 9, 2020. Under the Second Lease Amendment, the lease term with respect to the approximately 30,893 square feet of space leased under the Original Lease (the “Original Premises”) was extended for an additional period of five years commencing on April 1, 2023, and expiring as of March 31, 2028. During the extension period, the Company has agreed to pay an average base rent for the Original Premises of approximately $3.3 million per year, plus certain costs and expenses, including a proportionate share of applicable taxes, operating expenses and utilities. In addition, the Company received a tenant improvement allowance of up to $0.9 million. The foregoing description of the Second Lease Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Lease Amendment, a copy of which is attached as an exhibit this Quarterly Report on Form 10-Q.None.

Item 6. Exhibits


Exhibit Number	Exhibit Description	Filed with this Report	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/Reg. Number

4.1	~~Form~~Description of ~~Pre-Funded Warrant~~Securities of the Registrant and Comparison of Shareholder Rights		~~Form 8-K~~ ~~(Exhibit 4.1)~~	~~06/14/2022~~	~~001-37627~~

~~10.1~~	~~Second Amendment (to Lease) by and between Wave Life Sciences USA, Inc. and CPI/King 733 Concord Owner, LLC, dated as of August 8, 2022~~	X

31.1	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer	X

31.2	Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer	X

32*	Section 1350 Certifications of Principal Executive Officer and Principal Financial Officer	X

101.INS	Inline XBRL Instance Document – The instance document does not appear in the interactive data file because its Inline XBRL tags are embedded within the Inline XBRL ~~document.~~document	X

101.SCH	Inline XBRL Taxonomy Extension Schema Document	X

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document	X

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document	X

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document	X

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document	X

104	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)	X

(*) The certifications attached as Exhibit 32 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Wave Life Sciences Ltd. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.

3533

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	WAVE LIFE SCIENCES LTD.

Date: August ~~11, 2022~~3, 2023	By:	/s/ Paul B. Bolno, M.D., MBA
		Paul B. Bolno, M.D., MBA
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: August ~~11, 2022~~3, 2023	By:	/s/ Kyle Moran
		Kyle Moran
		Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

3634


Singapore (State or other jurisdiction of incorporation or organization)		~~00-0000000~~98-1356880 (I.R.S. Employer Identification No.)

7 Straits View #12-00, Marina One East Tower Singapore (Address of principal executive offices)		018936 (Zip Code)


Title of each class	Trading symbol	Name of each exchange on which registered
$0 Par Value Ordinary Shares	WVE	The Nasdaq Global Market


	June 30, 2022			December 31, 2021			June 30, 2023			December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$	123,163		$	150,564		$	172,974		$	88,497
Short-term investments		25,000			—
Prepaid expenses		5,396			6,584			9,012			7,932
Other current assets		6,555			5,416			2,722			2,108
Total current assets		160,114			162,564			184,708			98,537
Long-term assets:
Property and equipment, net		19,808			22,266
Property and equipment, net of accumulated depreciation of $40,423 and $37,846 as of June 30, 2023 and December 31, 2022, respectively								14,983			17,284
Operating lease right-of-use assets		28,791			18,378			24,805			26,843
Restricted cash		3,651			3,651			3,668			3,660
Other assets		955			148			1,821			62
Total long-term assets		53,205			44,443			45,277			47,849
Total assets	$	213,319		$	207,007		$	229,985		$	146,386
Liabilities, Series A preferred shares and shareholders’ equity
Liabilities, Series A preferred shares and shareholders’ equity (deficit)
Current liabilities:
Accounts payable	$	11,168		$	7,281		$	12,379		$	16,915
Accrued expenses and other current liabilities		11,085			14,861			10,429			17,552
Current portion of deferred revenue		37,466			37,098			111,133			31,558
Current portion of operating lease liability		4,363			4,961			6,285			5,496
Total current liabilities		64,082			64,201			140,226			71,521
Long-term liabilities:
Deferred revenue, net of current portion		75,256			77,479			104,540			79,774
Operating lease liability, net of current portion		35,160			24,955			28,875			32,118
Other liabilities								190			190
Total long-term liabilities		110,416			102,434			133,605			112,082
Total liabilities	$	174,498		$	166,635		$	273,831		$	183,603
Series A preferred shares, 0 par value; 3,901,348 shares issued and outstanding at June 30, 2022 and December 31, 2021	$	7,874		$	7,874
Shareholders’ equity:
Ordinary shares, 0 par value; 86,724,658 and 59,841,116 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	$	802,449		$	749,851
Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at June 30, 2023 and December 31, 2022							$	7,874		$	7,874
Shareholders’ equity (deficit):
Ordinary shares, no par value; 98,566,816 and 86,924,643 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively							$	839,675		$	802,833
Additional paid-in capital		113,169			87,980			124,601			119,442
Accumulated other comprehensive income (loss)		(47	)		181
Accumulated other comprehensive loss								(150	)		(29	)
Accumulated deficit		(884,624	)		(805,514	)		(1,015,846	)		(967,337	)
Total shareholders’ equity	$	30,947		$	32,498
Total liabilities, Series A preferred shares and shareholders’ equity	$	213,319		$	207,007
Total shareholders’ deficit							$	(51,720	)	$	(45,091	)
Total liabilities, Series A preferred shares and shareholders’ deficit							$	229,985		$	146,386


	Six Months Ended June 30,							Six Months Ended June 30,
	2022			2021				2023			2022
Cash flows from operating activities
Net loss	$	(79,110	)	$	(81,230	)		$	(48,509	)	$	(79,110	)
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:							Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of right-of-use assets		1,593			1,043				2,038			1,593
Depreciation of property and equipment		3,425			3,857				2,722			3,425
Share-based compensation expense		10,921			6,785				5,159			10,921
Changes in operating assets and liabilities:
Accounts receivable		—			30,000
Prepaid expenses		1,188			1,246				(1,080	)		1,188
Other assets		(1,946	)		(3,475	)			(2,373	)		(1,946	)
Accounts payable		3,264			(5,251	)			(4,456	)		3,264
Accrued expenses and other current liabilities		(3,776	)		(2,048	)			(7,123	)		(3,776	)
Deferred revenue		(1,855	)		(2,776	)			104,341			(1,855	)
Operating lease liabilities		(2,399	)		(1,792	)			(2,454	)		(2,399	)
Other non-current liabilities		0			(135	)
Net cash used in operating activities		(68,695	)		(53,776	)
Net cash provided by (used in) operating activities									48,265			(68,695	)
Cash flows from investing activities
Purchases of property and equipment		(700	)		(447	)			(561	)		(700	)
Proceeds from the sale of property and equipment		106			—
Proceeds from the sale property and equipment									—			106
Purchase of short-term investments		(50,000	)		—				—			(50,000	)
Proceeds from the maturity of short-term investments		25,000			—
Proceeds from maturity of short-term investments									—			25,000
Net cash used in investing activities		(25,594	)		(447	)			(561	)		(25,594	)
Cash flows from financing activities
Proceeds from issuance of ordinary shares, net of offering costs		51,464			—				34,623			51,464
Proceeds from issuance pre-funded warrants, net of offering costs		14,336			—
Proceeds from issuance of pre-funded warrants, net of offering costs									—			14,336
Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net of offering costs		1,105			13,150				1,764			1,105
Proceeds from the exercise of share options		37			200				86			37
Proceeds from the ESPP		174			336				429			174
Net cash provided by financing activities		67,116			13,686				36,902			67,116
Effect of foreign exchange rates on cash, cash equivalents and restricted cash		(228	)		(120	)			(121	)		(228	)
Net decrease in cash, cash equivalents and restricted cash		(27,401	)		(40,657	)
Net increase (decrease) in cash, cash equivalents and restricted cash									84,485			(27,401	)
Cash, cash equivalents and restricted cash, beginning of period		154,215			188,148				92,157			154,215
Cash, cash equivalents and restricted cash, end of period	$	126,814		$	147,491			$	176,642		$	126,814
Supplemental disclosure of cash flow information:
Supplemental disclosure of cash flow information
Increase in operating lease right-of-use assets and lease liabilities related to lease extension	$	12,006		$	—			$	—		$	12,006
Offering costs in accounts payable at period end	$	311		$	57			$	60		$	311


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐


		Page
PART I - FINANCIAL INFORMATION		5
Item 1. Financial Statements		5
Unaudited Consolidated Balance Sheets		5
Unaudited Consolidated Statements of Operations and Comprehensive Loss		6
Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)		7
Unaudited Consolidated Statements of Cash Flows		9
Notes to Unaudited Consolidated Financial Statements		10
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		2019
Item 3. Quantitative and Qualitative Disclosures About Market Risk		3331
Item 4. Controls and Procedures		3331
PART II - OTHER INFORMATION		3432
Item 1. Legal Proceedings		3432
Item 1A. Risk Factors		3432
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		3432
Item 3. Defaults Upon Senior Securities		3432
Item 4. Mine Safety Disclosures		3432
Item 5. Other Information		3432
Item 6. Exhibits		3533


	Total		Level 1		Level 2		Level 3
	(in thousands)
June 30, 2022
Cash and cash equivalents	$	123,163	$	123,163	$	—	$	—
Short-term investments		25,000		—		25,000		—
Restricted cash		3,651		3,651		—		—
Total	$	151,814	$	126,814	$	25,000	$	—
December 31, 2021
Cash and cash equivalents	$	150,564	$	150,564	$	—	$	—
Short-term investments		—		—		—		—
Restricted cash		3,651		3,651		—		—
Total	$	154,215	$	154,215	$	—	$	—